Substituted oxazole compounds with analgesic activity

ABSTRACT

Substituted oxazole derivatives corresponding to formula I: 
                         
a method for producing such compounds, pharmaceutical compositions containing such compounds, and the use of such compounds to treat pain, depression, urinary incontinence, diarrhoea, pruritus, alcohol and drug misuse, drug dependency, lethargy and/or anxiety.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of international patent application no. PCT/EP2006/012222, filed Dec. 19, 2006, designating the United States of America, and published in German on Jul. 19, 2007 as WO 2007/079928, the entire disclosure of which is incorporated herein by reference. Priority is claimed based on Federal Republic of Germany patent application no. DE 10 2005 061.429.9, filed Dec. 22, 2005.

BACKGROUND OF THE INVENTION

The present invention relates to substituted oxazole derivatives, processes for their preparation, medicaments containing these compounds, and the use of substituted oxazole derivatives for the preparation of medicaments.

The treatment of chronic and non-chronic pain states is extremely important in medicine. There is therefore a widespread need for highly effective pain treatments. The urgent need for a patient-friendly and targeted treatment of chronic and non-chronic pain states, which from the patient's point of view is hereinafter understood to mean the successful and satisfactory handling and treatment of pain, is well documented in the large number of scientific papers and articles that have appeared in recent years in the field of applied analgesics and in basic research on nociception.

Conventional opioids such as morphine are highly effective in the treatment of severe to extremely severe pain. Their use is however limited by their known side effects, for example respiratory depression, nausea, vomiting, sedation, constipation and development of tolerance. Also, they are less effective in neuropathic or incidental pain, including in particular tumour patients.

In Org. Lett 2001, 3, 877-880 oxazole derivatives are disclosed, which are likewise substituted in the 5-position with a secondary amine. These oxazole derivatives are however not substituted in the 2-position by a substituted alkyl chain with an aminomethyl-substituted cyclohexyl radical.

SUMMARY OF THE INVENTION

A basic object of the invention was to provide new analgesically effective substances that are suitable for treating pain, in particular also chronic and neuropathic pain.

The invention accordingly provides substituted oxazole derivatives of the general Formula I,

wherein

-   n is 0, 1 or 2; -   R¹ denotes an aryl or heteroaryl radical bonded via a C₁₋₃-alkylene     chain, in each case unsubstituted or monosubstituted or     polysubstituted; -   R² denotes aryl or heteroaryl, in each case unsubstituted or     monosubstituted or polysubstituted; an aryl radical bonded via a     C₁₋₃-alkylene chain, in each case unsubstituted or monosubstituted     or polysubstituted; -   R³ and R⁴ independently of one another denote C₁₋₆-alkyl, saturated     or unsaturated, branched or unbranched, unsubstituted or     monosubstituted or polysubstituted; aryl, unsubstituted or     monosubstituted or polysubstituted; an aryl radical bonded via a     C₁₋₃-alkylene chain, in each case unsubstituted or monosubstituted     or polysubstituted; or -   R³ and R⁴ together form a 5-, 6- or 7-membered ring, which can be     saturated or unsaturated but not aromatic, which optionally contains     a further heteroatom from the group S, O or N and in each case is     unsubstituted or monosubstituted or polysubstituted, wherein the     ring is optionally condensed to an aromatic ring; -   R⁵ and R⁶ independently of one another denote H; C₁₋₆-alkyl, in each     case saturated or unsaturated, branched or unbranched, wherein R⁵     and R⁶ do not simultaneously denote H; or -   R⁵ and R⁶ together denote CH₂CH₂OCH₂CH₂, or (CH₂)₃₋₆, -   R⁷ and R⁸ independently of one another denote C₁₋₆-alkyl, saturated     or unsaturated, branched or unbranched, unsubstituted or     monosubstituted or polysubstituted; an aryl or heteroaryl radical     bonded via a C₁₋₃-alkylene chain, in each case unsubstituted or     monosubstituted or polysubstituted; or -   R⁷ and R⁸ together form a 5-, 6- or 7-membered ring, which can be     saturated or unsaturated, but not aromatic, which optionally     contains a further heteroatom from the group S, O or N and is in     each case unsubstituted or monosubstituted or polysubstituted,     wherein the ring is optionally condensed to an aromatic ring,     in the form of the racemate; in the form of the enantiomers,     diastereomers, mixtures of the enantiomers or diastereomers, or of     an individual enantiomer or diastereomer; in the form of the bases     and/or salts of physiologically compatible acids. The compounds have     an affinity for the μ-opioid receptor.

The expressions “C₁₋₃-alkyl”, “C₁₋₄-alkyl” and “C₁₋₆-alkyl” include in the context of the present invention acyclic saturated or unsaturated hydrocarbon radicals, which can be branched or straight-chain, as well as unsubstituted or monosubstituted or polysubstituted, with 1 to 3 C atoms or 1 to 4 C atoms or 1 to 6 C atoms, i.e. C₁₋₃-alkanyls, C₂₋₃-alkenyls and C₂₋₃-alkinyls, or C₁₋₄-alkanyls, C₂₋₄-alkenyls and C₂₋₄-alkinyls, or C₁₋₆-alkanyls, C₂₋₆-alkenyls and C₂₋₆-alkinyls. In this connection alkenyls have at least one C—C double bond and alkinyls have at least one C—C triple bond. Advantageously alkyl is selected from the group comprising methyl, ethyl, n-propyl, 2-propyl, n-butyl, iso-butyl, sec.-butyl, tert.-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-hexyl, ethylenyl (vinyl), ethinyl, propenyl (—CH₂CH═CH₂, —CH═CH—CH₃, —C(═CH₂)—CH₃), propinyl (—CH—C≡CH, —C≡C—CH₃), butenyl, butinyl, pentenyl, pentinyl, hexenyl and hexinyl. Particularly preferred are methyl, ethyl, n-propyl, n-butyl, sec-butyl, iso-butyl.

If two substituents of a N atom “together form a 5-, 6- or 7-membered ring, which can be saturated or unsaturated but not aromatic, which optionally contains a further heteroatom from the group S, O or N”, this means in the context of the present invention that the two substituents form a ring that includes the N atom. Rings from the following group are advantageous: pyrrolidine, piperidine, azepan, piperazine, diazepan, imidazolidine, morpholine, thiomorpholine, oxazepan, thiazepan, oxazolidine or thiazolidine. Piperidine, piperazine, morpholine and thiomorpholine are particularly preferred.

The expression “aryl” denotes within the meaning of the present invention aromatic hydrocarbons, inter alia phenyls and naphthyls. The aryl radicals can also be condensed with further saturated, (partially) unsaturated or aromatic ring systems. Each aryl radical can be unsubstituted or monosubstituted or polysubstituted, wherein the aryl substituents can be identical or different and can be in any arbitrary and possible position of the aryl radical. Advantageously aryl is selected from the group containing phenyl, 1-naphthyl, 2-naphthyl, which can in each case be unsubstituted or monosubstituted or polysubstituted. The phenyl radical is particularly advantageous.

The expression “heteroaryl” denotes a 5-, 6- or 7-membered cyclic aromatic radical that contains at least 1, possibly also 2, 3, 4 or 5 heteroatoms, in which the heteroatoms are identical or different and the heterocycle can be unsubstituted or monosubstituted or polysubstituted; in the case of the substitution on the heterocycle, the substituents can be identical or different and can be in any arbitrary and possible position of the heteroaryl. The heterocycle can also be part of a bicyclic or polycyclic system. Preferred heteroatoms are nitrogen, oxygen and sulfur. It is preferred that the heteroaryl radical is selected from the group containing pyrrolyl, indolyl, furyl (furanyl), benzofuranyl, thienyl (thiophenyl), benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzodioxolanyl, benzodioxanyl, phthalazinyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazoyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, indazolyl, purinyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, carbazolyl, phenazinyl, phenothiazinyl or oxadiazolyl, wherein the bonding to the compounds of the general structure I can take place via any arbitrary and possible ring member of the heteroaryl radical. Pyridyl, furyl, thienyl and indolyl are particularly preferred.

The expression “aryl or heteroaryl bonded via C₁₋₃-alkylene” means, for the purposes of the present invention, that C₁₋₃-alkyl and aryl or heteroaryl have the meanings defined above and that the aryl or heteroaryl radical is bonded via a C₁₋₃-alkylene group to the compound of the general structure 1. Within the context of the present invention benzyl is particularly advantageous.

In connection with “alkyl” or a “5-, 6- or 7-membered ring, which can be saturated or unsaturated but not aromatic”, the term “substituted” is understood within the context of the present invention to denote the substitution of a hydrogen atom by F, Cl, Br, I, —CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, C₁₋₆-alkyl, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, S-benzyl, O—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl-OH, ═O, O-benzyl, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl or benzyl, wherein polysubstituted radicals are understood to be those radicals that are polysubstituted, for example disubstituted or trisubstituted, either on different atoms or on the same atoms, for example trisubstituted on the same C atom as in the case of CF₃ or —CH₂CF₃, or at different sites as in the case of —CH(OH)—CH═CH—CHCl₂. The polysubstitution can take place with the same or with different substituents. For the purposes of the present invention “monosubstituted or polysubstituted” in connection with alkyl or a saturated or unsaturated ring, which cannot be aromatic, particularly preferably denotes benzyl or methyl.

With regard to “aryl” and “heteroaryl”, within the context of the present invention “monosubstituted or polysubstituted” denotes monosubstitution or polysubstitution, for example disubstitution, trisubstitution or tetrasubstitution, of one or more hydrogen atoms of the ring system by F, Cl, Br, I, CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, O—C₁₋₆-alkyl-OH, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl, on one or possibly different atoms (in which connection a substituent can optionally for its part be substituted). The polysubstitution can in this connection be carried out with the same or with different substituents. For “aryl” and “heteroaryl” preferred substituents in this case are F, —Cl, —CF₃, —O—CH₃, methyl, ethyl, n-propyl, nitro, tert.-butyl and —CN. Particularly preferred are —F and —Cl.

The expression “salt formed with a physiologically compatible acid” is understood within the context of the present invention to mean salts of the respective active substance with inorganic or organic acids which are physiologically compatible, especially when used in humans and/or mammals. The hydrochloride is particularly preferred. Examples of physiologically compatible acids are: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid, 1,1-dioxo-1,2-dihydro1λ⁶-benzo[d]isothiazol-3-one (saccharinic acid), monomethylsebacic acid, 5-oxo-proline, hexane-1-sulfonic acid, nicotinic acid, 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethylbenzoic acid, α-lipoic acid, acetylglycine, hippuric acid, phosphoric acid and/or aspartic acid. Hydrochloric acid is particularly preferred.

The groups (CH₂)₃₋₆ and (CH₂)₄₋₅ are understood to denote —CH₂—CH₂—CH₂—, —CH₂—CH₂—CH₂—CH₂—, —CH₂—CH₂—CH₂—CH₂—CH₂— and CH₂—CH₂—CH₂—CH₂—CH₂—CH₂—, and —CH₂—CH₂—CH₂—CH₂— and —CH₂—CH₂—CH₂—CH₂—CH₂.

Preferred within the meaning of the present invention are oxazole derivatives in which R¹ denotes an aryl or heteroaryl radical bonded via a C₁₋₃-alkylene chain, in each case unsubstituted or monosubstituted or polysubstituted with F, Cl, Br, I, CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, O—C₁₋₆alkyl-OH, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl.

Preferably R¹ denotes a phenyl radical bonded via a C₁₋₃-alkylene chain, unsubstituted or monosubstituted or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl. Particularly preferred are oxazole derivatives in which R¹ denotes benzyl.

Preferred in the context of the present invention are also substituted oxazole derivatives, in which R² denotes phenyl, thienyl or pyridyl, in each case unsubstituted or monosubstituted or polysubstituted with F, Cl, CN, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, O—C₁₋₆-alkyl-OH, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl; an aryl radical bonded via a C₁₋₃-alkylene chain, in each case unsubstituted or monosubstituted or polysubstituted with F, Cl, CN, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl —OH, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, O—C₁₋₆-alkyl-OH, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₆-alkyl, CF₃, C₁₋₆-alkyl.

Preferably R² denotes phenyl or thienyl, in each case unsubstituted or monosubstituted or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl; a phenyl radical bonded via a C₁₋₃-alkylene chain, in each case unsubstituted or monosubstituted or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl.

In particular, R² denotes phenyl, unsubstituted or monosubstituted or polysubstituted with F, Cl, OH, OCH₃, CF₃ or CH₃; thienyl; or a phenyl radical bonded via a C₁₋₃-alkylene chain, unsubstituted or monosubstituted or polysubstituted with F, Cl, CN, OH, OCH₃, CF₃ or CH₃.

Most particularly preferred are oxazole derivatives in which R² denotes phenyl, unsubstituted or monosubstituted with Cl or F, or thienyl.

Also preferred in the context of the present invention are substituted oxazole derivatives, in which R³ and R⁴ independently of one another denote C₁₋₆-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or monosubstituted or polysubstituted with F, Cl, Br, I, —CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, C₁₋₆-alkyl, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, S-benzyl, O—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl-OH, ═O, O-benzyl, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl or benzyl; aryl, unsubstituted or monosubstituted or polysubstituted with F, Cl, Br, I, CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, O—C₁₋₆-alkyl-OH, C(═O)C₁₋₁₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl; an aryl radical bonded via a C₁₋₃-alkylene chain, in each case unsubstituted or monosubstituted or polysubstituted with F, Cl, Br, I, CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, N(C₁₋₆alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, O—C₁₋₆-alkyl-OH, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl.

Other preferred compounds are those in which R³ and R⁴ together form a 5-, 6- or 7-membered ring, which can be saturated or unsaturated, but not aromatic, which optionally contains a further heteroatom from the group S, O or N and is in each case unsubstituted or can be monosubstituted or polysubstituted with F, Cl, Br, I, —CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, C₁₋₆-alkyl, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, S-benzyl, O—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl-OH, ═O, O-benzyl, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl or benzyl, wherein the ring is optionally condensed with an aromatic ring.

Preferably R³ and R⁴ independently of one another denote C₁₋₆-alkyl, unsubstituted or monosubstituted or polysubstituted with F, Cl, —CN, SH, S—C₁₋₆-alkyl, benzyl, OH, O-benzyl, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl; or phenyl, unsubstituted or monosubstituted or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃ or C₁₋₆-alkyl; or R³ and R⁴ together denote —CH₂CH₂OCH₂CH₂—, —CH₂CH₂NR⁹CH₂CH₂—, —(CH₂)₄₋₅— or

wherein R⁹ denotes a phenyl group bonded via a C₁₋₃-alkylene chain, in each case unsubstituted or monosubstituted or polysubstituted with F, Cl, Br, I, CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, O—C₁₋₆alkyl-OH, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl; or denotes C₁₋₆-alkyl.

Most particularly preferred are oxazole derivatives in which R³ and R⁴ independently of one another denote phenyl, ethyl or methyl, or the radicals R³ and R⁴ together denote CH₂CH₂OCH₂CH₂, CH₂CH₂NR⁹CH₂CH₂, (CH₂)₄₋₅ or

wherein R⁹ denotes benzyl, 4-F-phenyl or 4-methoxyphenyl.

Also preferred in the context of the present invention are oxazole derivatives in which R⁵ and R⁶ independently of one another denote H or C₁₋₆-alkyl, wherein R⁵ and R⁶ do not simultaneously denote H, or R⁵ and R⁶ together denote —CH₂CH₂OCH₂CH₂— or —(CH₂)₄₋₅—.

Particularly preferred are oxazole derivatives in which R⁵ and R⁶ denote CH₃.

Also preferred are oxazole derivatives in which R⁷ and R⁸ independently of one another denote C₁₋₆-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or monosubstituted or polysubstituted with F, Cl, Br, I, —CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, C₁₋₆-alkyl, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, S-benzyl, O—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl-OH, ═O, O-benzyl, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl or benzyl; an aryl radical bonded via a C₁₋₃-alkylene chain, in each case unsubstituted or monosubstituted or polysubstituted with F, Cl, Br, I, CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, O—C₁₋₆-alkyl-OH, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, C₁₋₆-alkyl.

Alternative preferred compounds are those in which R⁷ and R⁸ together form a 5-, 6- or 7-membered ring, which can be saturated or unsaturated but not aromatic, which optionally contains a further heteroatom from the group S, O or N and in each case can be unsubstituted or monosubstituted or polysubstituted with F, Cl, Br, I, —CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, C₁₋₆-alkyl, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, S-benzyl, O—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl-OH, ═O, O-benzyl, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl or benzyl, wherein the ring is optionally condensed with an aromatic ring.

In particular, R⁷ and R⁸ independently of one another preferably denote benzyl or phenethyl, in each case unsubstituted or monosubstituted or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃ or C₁₋₆-alkyl; or R⁷ and R⁸ together denote —CH₂CH₂SCH₂CH₂—, —CH₂CH₂OCH₂CH₂—, —(CH₂)₄—, —(CH₂)₅—, —CH₂CH₂NR¹⁰CH₂CH₂—, wherein individual H atoms can be replaced by C₁₋₄-alkyl, branched or unbranched, unsubstituted or monosubstituted or polysubstituted with OH, OCH₃, CN, F, Cl, SH, SCH₃, CF₃ or benzyl; wherein R¹⁰ denotes phenyl, benzyl or phenethyl, unsubstituted or monosubstituted or polysubstituted with CH₃, OCH₃, OH, F, Cl, CN, SH, SCH₃ or CF₃.

Most particularly preferred are oxazole derivatives in which R⁷ and R⁸ independently of one another denote methyl, ethyl, benzyl or phenethyl; or R⁷ and R⁸ denote —CH₂CH₂SCH₂CH₂—, —CH₂CH₂OCH₂CH₂—, —(CH₂)₄— or —(CH₂)₅—, —CH₂CH₂NR¹⁰CH₂CH₂—, wherein individual H atoms can be replaced by methyl or benzyl, and R¹⁰ denotes phenyl, 4-methoxyphenyl or benzyl;

It is also preferred that n is 0 or 1.

Most particularly preferred are substituted oxazole derivatives selected from the group consisting of:

-   17.     [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-piperidin-1-yl-methyl]-cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine -   18.     ((4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-methylphenylamine -   19.     ([4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-methylphenylamine -   20.     ([4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-methyl)-diethylamine -   21.     benzyl-[4-benzyl-2-({[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-diethylaminomethyl)-oxazol-5-yl]-methylamine -   22.     benzyl-{4-benzyl-2-[{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-(methylphenylamine)-methyl]-oxazol-5-yl}-methylamine -   23.     [(4-{[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   24.     [(4-{[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   25.     benzyl-(4-benzyl-2-{[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-piperidin-1-yl-methyl}-oxazol-5-yl)-methylamine -   26.     [(4-{[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   27.     {[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine -   28.     {[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine -   29.     {[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine -   30.     benzyl-(4-benzyl-2-{diethylamino-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-oxazol-5-yl)-methylamine -   31.     {[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine -   32.     ({4-[[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-(4-benzylpiperazin-1-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   33.     [(4-{[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-(4-fluorophenyl)-methyl]-dimethylamine -   34.     [4-benzyl-2-(diethylamino-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-oxazol-5-yl]-methylphenethylamine -   35.     [4-benzyl-2-(diethylamino-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-oxazol-5-yl]-diethylamine -   36.     ([4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-diethylamine -   37.     ([4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-methylphenylamine -   38.     {4-benzyl-2-[{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-(methylphenylamine)-methyl]-oxazol-5-yl}-methylphenethylamine -   39.     [4-benzyl-2-({4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-piperidin-1-yl-methyl)-oxazol-5-yl]-diethylamine -   40.     [(4-{[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine -   41.     ([4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-methyl)-diethylamine -   42.     ([4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-methyl)-methylphenylamine -   43.     {4-benzyl-2-[{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-(methylphenylamine)-methyl]-oxazol-5-yl}-methylphenethylamine -   44.     [4-benzyl-2-((4-benzylpiperazin-1-yl)-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-methyl)-oxazol-5-yl]-diethylamine -   45.     [(4-{[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   46.     (4-benzyl-2-{[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-piperidin-1-yl-methyl}-oxazol-5-yl)-methylphenethylamine -   47.     (4-benzyl-2-{[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-piperidin-1-yl-methyl}-oxazol-5-yl)-diethylamine -   48.     ({4-[(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-piperidin-1-yl-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   49.     (4-benzyl-2-{diethylamino-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-oxazol-5-yl)-methylphenethylamine -   50.     (4-benzyl-2-{diethylamino-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-methyl}-oxazol-5-yl)-diethylamine -   51.     {[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine -   52.     {(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-methylphenylamine -   53.     ({4-[[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-(4-benzylpiperazin-1-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   54.     (4-benzyl-2-{(4-benzylpiperazin-1-yl)-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-oxazol-5-yl)-methylphenethylamine -   55.     ({4-[(4-benzylpiperazin-1-yl)-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   56.     [(4-{2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine -   57.     [(4-{2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine -   58.     benzyl-[4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylamine -   59.     (1-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine -   60.     (1-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine -   61.     benzyl-[4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-diethylaminoethyl)-oxazol-5-yl]-methylamine -   62.     [{4-[2-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine -   63.     [{4-[2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine -   64.     [{4-[2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl-piperazin-1-yl)-ethyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine -   65.     [(4-{2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-(4-fluorophenyl)-methyl]-dimethylamine -   66.     benzyl-[4-benzyl-2-(2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylamine -   67.     (1-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine -   68.     (1-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine -   69.     (1-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine -   70.     benzyl-[4-benzyl-2-(1-diethylamino-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-methylamine -   71.     [{4-[2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine -   72.     [(4-{2-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   73.     [(4-{2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   74.     [(4-{2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   75.     benzyl-(4-benzyl-2-{2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-1-piperidin-1-yl-ethyl}-oxazol-5-yl)-methylamine -   76.     [(4-{2-[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   77.     {1-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine -   78.     {1-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine -   79.     {1-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine -   80.     benzyl-(4-benzyl-2-{1-diethylamino-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-oxazol-5-yl)-methylamine -   81.     ({4-[2-[4-benzyl-5-(4-benzyl-piperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   82.     ({4-[2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   83.     ({4-[2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   84.     benzyl-(4-benzyl-2-{1-(4-benzylpiperazin-1-yl)-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-oxazol-5-yl)-methylamine -   85.     ({4-[2-[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   86.     [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylphenethylamine -   87.     [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-diethylamine -   88.     (1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine -   89.     [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-diethylaminoethyl)-oxazol-5-yl]-methylphenethylamine -   90.     [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-diethylaminoethyl)-oxazol-5-yl]-diethylamine -   91.     (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine -   92.     (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-methylphenylamine -   93.     [4-benzyl-2-(1-(4-benzylpiperazin-1-yl)-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-methylphenethylamine -   94.     [4-benzyl-2-(1-(4-benzylpiperazin-1-yl)-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-diethylamine -   95.     [4-benzyl-2-(2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylphenethylamine -   96.     (1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine -   97.     [4-benzyl-2-(1-diethylamino-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-methylphenethylamine -   98.     [4-benzyl-2-(1-diethylamino-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-diethylamine -   99.     (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine -   100.     (1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine -   101.     (1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-methylphenylamine -   102.     {4-benzyl-2-[2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1-(methylphenylamine)-ethyl]-oxazol-5-yl}-methylphenethylamine -   103.     {4-benzyl-2-[2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1-(methylphenylamine)-ethyl]-oxazol-5-yl}-diethylamine -   104.     (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-methylphenylamine -   105.     (1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-methylphenylamine -   106.     [{4-[2-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine -   107.     [(4-{2-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   108.     (4-benzyl-2-{2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-1-piperidin-1-yl-ethyl}-oxazol-5-yl)-methylphenethylamine -   109.     (4-benzyl-2-{2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-1-piperidin-1-yl-ethyl}-oxazol-5-yl)-diethylamine -   110.     ({4-[2-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-piperidin-1-yl-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   111.     [(4-{2-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   112.     {1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine -   113.     (4-benzyl-2-{1-diethylamino-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-oxazol-5-yl)-methylphenethylamine -   114.     (4-benzyl-2-{1-diethylamino-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-oxazol-5-yl)-diethylamine -   115.     {1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine -   116.     {1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine -   117.     {1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-methylphenylamine -   118.     ({4-[2-(4-benzylpiperazin-1-yl)-2-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   119.     ({4-[2-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   120.     [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine -   121.     [{4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine -   122.     [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-fluorophenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine -   123.     [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine -   124.     [(4-{(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine -   125.     [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine -   126.     [{4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine -   127.     [{4-[{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine -   128.     [{4-[[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine -   129.     [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine -   130.     [{4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine -   131.     [[4-({4-benzyl-5-[4-(4-methoxy-phenyl)-piperazin-1-yl]-oxazol-2-yl}-morpholin-4-yl-methyl)-cyclohexyl]-(4-chlorophenyl)-methyl]-dimethylamine -   132.     [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-morpholin-4-yl-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine -   133.     [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-fluorophenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine -   134.     [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine -   135.     [(4-{(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine -   136.     [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine -   137.     [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine -   138.     ({4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   139.     ({4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   140.     {[4-({4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-morpholin-4-yl-methyl)-cyclohexyl]-thiophen-2-yl-methyl}-dimethylamine -   141.     [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-morpholin-4-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   142.     [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-fluorophenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   143.     [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   144.     [(4-{(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   145.     [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   146.     ({4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   147.     ({4-[{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   148.     ({4-[[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   149.     [{4-[2-(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-2-morpholin-4-yl-ethyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine -   150.     [{4-[2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-morpholin-4-yl-ethyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine -   151.     [[4-(2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-morpholin-4-yl-ethyl)-cyclohexyl]-(3-fluorophenyl)-methyl]-dimethylamine -   152.     [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-morpholin-4-yl-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine -   153.     [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine -   154.     [(4-{2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-[4-(4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine -   155.     [(4-{2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-[4-(4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine -   156.     [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-[4-(4-methoxy-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine -   157.     [{4-[2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-(3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine -   158.     ({4-[2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-morpholin-4-yl-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine -   159.     {[4-(2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-morpholin-4-yl-ethyl)-cyclohexyl]-thiophen-2-yl-methyl}-dimethylamine -   160.     [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-morpholin-4-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   161.     [(4-{2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   162.     [(4-{2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   163.     [(4-{2-(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-2-[4-(4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   164.     [(4-{2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-[4-(4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   165.     [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-[4-(4-methoxy-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine -   166.     ({4-[2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-(3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine

The invention also provides a method for the preparation of an oxazole derivative according to the invention. The substances according to the invention can be prepared by heating aldehydes of the general Formula A with amines of the general Formula B and isonitrile amides of the general Formula C in an organic solvent, for example methanol or ethanol, for 1 to 10 hours at a temperature between 30° and 100° C., preferably 40 to 80° C.

The component C can be prepared analogously to the synthesis described in K. Numani et al, Agric. Biol. Chem. 1985, 49, 10, 3023-3028 according to the following reaction scheme. After preparation of the corresponding amino acid ester, as described in V. Wehner et al., Tetrahedron 2004, 60, 19, 4295-4302, the isonitrile ester is formed under dehydrating conditions. After subsequently reacting the ester with an amine, the desired isonitrile amide is obtained.

The amines of the general Formula B are commercially obtainable or can be prepared by methods known to the person skilled in the art.

In order to prepare the aldehydes of the general Formula A, the keto function of 4-oxo-cyclohexanecarboxylic acid esters,

where E denotes a C₁₋₆-alkyl radical, preferably ethyl, is protected by methods known to those skilled in the art

S₁ and S₂ each denote a protective group, preferably form a ring, and together denote —CH₂—CH₂—. The ester 10 is reduced with a reducing agent, for example diisobutyl aluminium hydride to form the aldehyde 11.

By adding an amine of the general Formula R⁵R⁶NH and a cyanide, for example KCN or NaCN, the aldehyde 11 is converted under the addition of an acid, for example hydrochloric acid, in an organic solvent, for example methanol or ethanol, to the nitrile 12.

The nitrile 12 is reacted with a Grignard reagent of the general Formula R²MgHal, where Hal denotes Br, Cl or I, or an organometallic compound of the general Formula R²Li in an organic solvent, for example diethyl ether, dioxane or tetrahydrofuran, to form a compound of the general Formula 13.

The protective groups are split off by conventional methods to obtain the ketone 14.

The aldehyde 15

is obtained by reacting the ketone 14 with (methoxymethyl)triphenylphosphonium chloride and a strong base, for example potassium tert-butylate, at a temperature from −20° C. to +30° C.

By reacting the aldehyde 15 with (methoxymethyl)triphenylphosphonium chloride and a strong base, for example potassium tert-butylate, at a temperature from −20° C. to +30° C., an aldehyde of the general Formula 16 is obtained.

By repeating the last reaction step aldehydes can be obtained in which n is 2.

The substances according to the invention are suitable as pharmaceutical active substances in medicaments. The invention accordingly also provides medicaments containing at least one substituted oxazole derivatives according to the invention, as well as optionally suitable additives and/or auxiliary substances and/or optionally further active substances.

The medicaments according to the invention contain, in addition to at least one substituted oxazole derivative according to the invention, optionally also suitable additives and/or auxiliary substances, thus also carrier materials, fillers, solvents, diluents, colorants and/or binders, and can be administered as liquid medicament in the form of injection solutions, drops or juices, or as semi-solid medicament in the form of granules, tablets, pellets, patches, capsules, plasters or aerosols. The choice of the auxiliary substances, etc. as well as the amounts thereof to be employed depends on whether the medicament is to be administered orally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or topically, for example to the skin, mucus membranes or the eyes. For oral application suitable preparations are in the form of tablets, pills, capsules, granules, drops, juices and syrups, while for parenteral, topical and inhalative application suitable preparations are solutions, suspensions, easily reconstitutable dry preparations as well as sprays. Oxazole derivatives according to the invention in a depot form, in dissolved form or in a plaster, optionally with the addition of agents promoting penetration of the skin, are suitable percutaneous application forms. Orally or percutaneously employable preparation forms can release the oxazole derivatives according to the invention in a delayed manner. In principle other active substances known to the person skilled in the art can also be added to the medicaments according to the invention.

The amount of active substance to be administered to the patient varies depending on the patient's weight, type of application, medical indications and the severity of the disease. Normally 0.005 to 20 mg/kg, preferably 0.05 to 5 mg/kg of at least one oxazole derivative according to the invention are administered. The medicament can contain an oxazole derivative according to the invention as pure diastereomer and/or enantiomer, as racemate, or as a non-equimolar or equimolar mixture of the diastereomers and/or enantiomers.

The invention also provides for the use of an oxazole derivative according to the invention for the treatment of pain or preparation of a medicament for treating pain, in particular acute, neuropathic or chronic pain.

The invention also provides for the use of an oxazole derivative according to the invention for the treatment of depression or the preparation of a medicament for treating depression and/or anxiety.

In addition the substituted oxazole derivatives of the general Formula I can be used to treat urinary incontinence, diarrhoea, pruritus, alcohol and drug misuse, drug dependence and lack of drive or lethargy.

The invention accordingly also provides for the use of a substituted oxazole derivative of the general Formula I for the preparation of a medicament for treating urinary incontinence, diarrhoea, pruritus, alcohol and drug misuse, drug dependence and lack of drive or lethargy.

EXAMPLES Preparation of the Isonitrile Amide Methyl 2-(formylamino)-3-phenylpropanoate 2i

Cyanomethyl formate (Aldrich, Order No. 453579, 5.05 g, 59.3 mmole) was suspended together with the phenylalanine methyl ester hydrochloride (Aldrich, Order No. 525472, 12.80 g, 59.3 mmole) in 80 ml dichloromethane and cooled to 0° C. in an ice bath. Triethylamine (6.01 g, 59.3 mmole) dissolved in 15 ml of dichloromethane was then added and the mixture was stirred for 16 hours at room temperature. A clear solution formed. In order to work up the mixture the latter was diluted with 100 ml of dichloromethane and washed firstly with 200 ml of saturated NaHCO₃ solution and then twice with saturated NaCl solution. The organic phase was dried over magnesium sulfate and concentrated by evaporation. The product obtained was used without further purification for the next stage.

Yield: 12.5 g colorless oil ¹H-NMR (300 MHz, CDCl₃): δ=3.07-3.22 (m, 2H); 3.74 (s, 3H); 4.92-5.01 (m, 1H); 6.20 (bs, 1H); 7.07-7.15 (m, 2H); 7.23-7.34 (m, 3H); 8.15 (s, 1H).

Methyl 2-isocyano-3-phenylpropionate 3i

Methyl 2-(formylamino)-3-phenylpropanoate 2i (2.00 g, 9.7 mmole) was dissolved in 20 ml of dichloromethane and cooled to 0° C. After addition of triethylamine (4.88 g, 48.3 mmole), phosphorous oxychloride (2.22 g, 14.5 mmole) dissolved in 10 ml of dichloromethane was then slowly added dropwise. The initially colorless solution turned yellow, with the formation finally of an orange solid. After stirring for 1 hour in an ice bath potassium carbonate solution (0.8 M in water, 39 ml) was slowly added dropwise. To work up the mixture the phases were separated. The organic phase was first of all washed twice with water, each time 20 ml, and then once with 20 ml of saturated NaCl solution. The solution was dried over sodium sulfate and concentrated by evaporation. The product was used without further purification for the next stage.

Yield: m=1.55 g of orange-brown liquid ¹H-NMR (300 MHz, CDCl₃): δ=3.14 (dd, 1H, J_(AA′)=8.66 Hz, J_(AB)=8.29 Hz); 3.23 (dd, 1H, J_(AA′)=4.52 Hz, J_(AB)=4.90 Hz); 3.80 (s, 3H), 4.46 (dd, 1H, J=8.29; J=4.90 Hz); 7.22-7.39 (m, 5H).

General Procedure:

Methyl 2-isocyano-3-phenyl-propionate 3i (13 g, 68.71 mmole) and the corresponding amine (137.42 mmole) were mixed together and stirred at room temperature. After completion of the reaction (TLC check) the product was first of all concentrated by evaporation on a rotary evaporator and then purified by column chromatography (solvent: gradient:hexane to ether:hexane=1:1)

1-[(2R)-2-isocyano-3-phenylpropanoyl]piperidine 4a (NR⁷R⁸=piperidinyl)

¹H-NMR (300 MHz, CDCl₃): δ=1.26-1.44 (m, 1H); 1.46-1.73 (m, 5H); 3.10-3.34 (m, 2H); 3.35-3.56 (m, 2H); 3.57-3.69 (m, 1H); 4.66 (dd, 1H, J=6.03 Hz, J=9.0 Hz); 7.23-7.39 (m, 5H).

1-[(2R)-2-isocyano-3-phenylpropanoyl]pyrrolidine 4b (NR⁷R⁸=pyrrolidinyl)

¹H-NMR (300 MHz, CDCl₃): δ=1.70-1.99 (m, 4H); 2.98-3.11 (m, 1H); 3.12-3.35 (m, 2H); 3.36-3.59 (m, 3H); 4.40 (dd, 1H, JA,B=7.53 Hz, JA,B′=7.16 Hz); 7.23-7.38 (m, 5H).

4-[(2R)-2-isocyano-3-phenylpropanoyl]morpholine 4c (NR⁷R⁸=morpholinyl)

¹H-NMR (300 MHz, CDCl₃): δ=3.13-3.52 (m, 5H); 3.52-3.80 (m, 5H); 4.47-4.61 (m, 1H); 7.19-7.43 (m, 5H).

(2R)-1-(4-benzylpiperidin-1-yl)-2-isocyano-3-phenylpropan-1-one 4d (NR⁷R⁸=4-benzylpiperidinyl)

¹³C-NMR (75 MHz, CDCl₃) both diastereomers: δ=31.45, 31.80 (t); 37.77, 38.18 (d); 38.82, 39.25 (t); 42.68, 42.73 (t); 43.21 (t); 46.11, 46.34 (t); 55.10, 55.60 (d); 126.15 (d); 127.51, 127.60 (d); 128.36 (d); 128.74, 128.87 (d); 129.01, 129.05 (d); 129.39, 129.51 (d); 135.32, 135.53 (s); 139.55, 139.71 (s); 162.86, 163.07 (s).

(2R)-1-(4-benzylpiperazin-1-yl)-2-isocyano-3-phenylpropan-1-one 4e (NR⁷R⁸=4-benzylpiperazinyl)

¹³C-NMR (75 MHz, CDCl₃): δ=38.95 (t); 42.73 (t); 45.93 (t); 52.32 (t); 55.33 (d); 62.66 (t); 127.37 (d); 127.67 (d); 128.38 (d); 128.84 (d); 129.07 (d); 129.41 (d); 135.25 (s); 137.36 (s); 163.12 (s).

(2R)-2-isocyano-1-(4-methylpiperidin-1-yl)-3-phenylpropan-1-one 4f (NR⁷R⁸=4-methylpiperidinyl)

¹³C-NMR (75 MHz, CDCl₃) both diastereomers: δ=21.47 (q); 21.51 (q); 30.68 (d); 30.96 (d); 33.42 (t); 33.82 (t); 33.94 (t); 38.83 (t); 39.20 (t); 43.26 (t); 43.29 (t); 46.17 (t); 46.37 (t); 55.18 (d); 55.64 (d); 127.50 (d); 127.57 (d); 128.75 (d); 128.84 (d); 129.40 (d); 129.47 (d); 135.36 (s); 135.58 (s); 162.88 (s); 163.07 (s).

(2R)—N-benzyl-2-isocyano-N-methyl-3-phenylpropanamide 4g (R⁷=methyl, R⁸=benzyl)

¹H-NMR (300 MHz, CDCl₃): δ=2.85 (s, 3H); 3.11-3.40 (m, 2H); 4.30-4.66 (m, 3H); 7.12-7.21 (m, 2H); 7.24-7.39 (m, 8H).

(2R)-2-isocyano-3-phenyl-1-(4-phenylpiperazin-1-yl)-propan-1-one 4h (NR⁷R⁸=4-phenylpiperazinyl)

¹H-NMR (300 MHz, CDCl₃): δ=3.06-3.90 (m, 10H); 4.60 (dd, 1H, J=6.78 Hz, J=6.0 Hz); 6.83-6.98 (m, 3H); 7.22-7.42 (m, 7H).

1-(3,5-dimethylpiperidin-1-yl)-2-isocyano-3-phenylpropan-1-one 41 (NR⁷R³=3,5-dimethylpiperidinyl)

¹H-NMR (300 MHz, CDCl₃) both diastereomers: δ=0.68-0.80 (m, 2H); 0.80-0.96 (m, 12H); 0.99-1.14 (m, 1H); 1.38-1.53 (m, 1H); 1.63-1.90 (m, 4H); 1.97-2.13 (m, 2H); 2.31-2.44 (m, 1H); 2.49-2.61 (m, 1H); 3.10-3.67 (m, 6H); 4.48-4.63 (m, 4H); 7.21-7.40 (m, 10H).

(2R)-2-isocyano-N-methyl-N-phenethyl-3-phenylpropionamide 4j (R⁷=methyl, R⁸=2-phenylethyl)

¹³C-NMR (75 MHz, CDCl₃) both rotamers: δ=33.31 (t); 36.18 (q); 38.66 (t); 38.82 (t); 51.04 (t); 51.36 (t); 54.97 (d); 55.66 (d); 126.59 (d); 127.24 (d); 127.45 (d); 127.59 (d); 128.64 (d); 128.78 (d); 128.83 (d); 129.10 (d); 129.36 (d); 129.41 (d); 135.35 (s); 137.51 (s); 138.41 (s); 164.36 (s); 164.82 (s).

(2R)—N,N-diethyl-2-isocyano-3-phenylpropionamide 4k (R⁷=ethyl, R⁸=ethyl)

¹H-NMR (300 MHz, CDCl₃): δ=1.10 (t, 3H, J=7.16 Hz); 1.11 (t, 3H, J=7.16 Hz); 3.09-3.47 (m, 6H); 4.49 (t, 1H, J=7.16 Hz); 7.22-7.38 (m, 5H).

4-[(2R)-2-isocyano-3-phenylpropanoyl]thiomorpholine 4l (NR⁷R⁸=thiomorpholinyl)

¹H-NMR (300 MHz, CDCl₃): δ=2.24-2.40 (m, 1H), 2.43-2.65 (m, 3H); 2.94-3.17 (m, 2H); 3.64-3.81 (m, 4H); 5.28 (dd, 1H, J=8.67 Hz, J=6.03 Hz); 7.24-7.39 (m, 5H).

1-[(2S)-2-isocyano-3-phenylpropanoyl]-4-(4-methoxyphenyl)piperazine 4m (NR7³R⁸=1-(4-methoxyphenyl)piperazinyl

¹H-NMR (300 MHz, CDCl₃): δ=2.74-2.83 (m, 1H); 2.93-3.10 (m, 3H); 3.13-3.88 (m, 7H); 3.77 (s, 3H); 4.60 (dd, 1H, J=8.10 Hz, J=6.59 Hz); 6.84-6.86 (m, 4H); 7.26-7.38 (m, 5H).

1-[2-isocyano-3-phenylpropanoyl]-3-methylpiperidine 4n (NR⁷R⁸=3-methylpiperidinyl)

¹H-NMR (300 MHz, CDCl₃) diastereomers and rotamers: δ=0.82-0.94 (m, 3H); 1.01-1.91 (m, 5H); 2.20-3.76 (m, 4H); 4.28-4.65 (m, 2H); 7.23-7.39 (m, 5H).

2-isocyano-1-morpholin-4-yl-3-phenylpropan-1-one 4o (NR⁷R⁸=2,6-dimethylmorpholinyl)

¹H-NMR (300 MHz, CDCl₃) diasteromers and rotamers: δ=1.04-1.27 (m, 6H); 2.26-3.80 (m, 8H); 4.34-4.63 (m, 2H); 7.16-7.39 (m, 5H).

1-[4-(2-fluorophenyl)-piperazin-1-yl]-2-isocyano-3-phenylpropan-1-one 4p (NR⁷R⁸=1-(2-fluorophenyl)piperazinyl)

¹H-NMR (300 MHz, CDCl₃): δ=2.77-2.85 (m, 1H); 2.96-3.10 (m, 3H); 3.16-3.37 (m, 2H); 3.38-3.50 (m, 1H); 3.59-3.77 (m, 2H); 3.83-3.92 (m, 1H); 4.60 (dd, 1H, J=8.10 Hz, J=6.59 Hz), 6.84-6.91 (m, 1H); 6.96-7.10 (m, 3H); 7.26-7.39 (m, 5H).

1-[4-(4-fluorophenyl)-piperazin-1-yl]-2-isocyano-3-phenylpropan-1-one 4q (NR⁷R⁸=1-(4-fluorophenyl)piperazinyl)

¹H-NMR (300 MHz, CDCl₃): δ=2.77-2.85 (m, 1H); 3.00-3.11 (m, 3H); 3.17-3.46 (m, 3H); 3.57-3.77 (m, 2H); 3.80-3.89 (m, 1H); 4.60 (dd, 1H, J=8.10 Hz, J=6.78 Hz), 6.82-6.88 (m, 2H); 6.94-7.01 (m, 2H); 7.25-7.39 (m, 5H).

General Procedure:

Methyl 2-isocyano-2-phenylacetate 5 (13 g, 68.71 mmole) and the corresponding amine (137.42 mmole) were mixed together and stirred at room temperature. After completion of the reaction (TLC check) the mixture was first of all concentrated by evaporation on a rotary evaporator and then purified by column chromatography (solvent: gradient:hexane to ether:hexane=1:1)

2-isocyano-2-phenyl-1-pyrrolidin-1-yl-ethanone 6a (NR⁷R⁸=pyrrolidinyl)

¹H-NMR (300 MHz, CDCl₃): δ=1.74-1.99 (m, 4H); 3.25-3.63 (m, 4H); 5.51 (s, 1H); 7.38-7.53 (m, 5H).

2-isocyano-1-morpholin-4-yl-2-phenylethanone 6b (NR⁷R⁸=morpholinyl)

¹H-NMR (300 MHz, CDCl₃): δ=3.30-3.48 (m, 4H); 3.59-3.70 (m, 4H); 5.66 (s, 1H); 7.37-7.50 (m, 5H).

2-isocyano-2-phenyl-1-(piperidin-1-yl)ethanone 6c (NR⁷R⁸=piperidinyl)

¹H-NMR (300 MHz, CDCl₃): δ=1.22-1.36 (m, 2H); 1.47-1.65 (m, 4H); 3.29 (t, J=4.90 Hz, 2H); 3.50-3.65 (m, 2H); 5.67 (s, 1H); 7.36-7.46 (m, 5H).

3-(4-chlorophenyl)-2-isocyano-1-piperidin-1-yl-propan-1-one 8

Methyl 2-isocyano-2-(4-chlorophenyl)propionate 7 (Priaton, Order No. 224.8 g, 35.87 mmole) and piperidine (6.1 μg, 71.74 mmole) were mixed together and stirred at room temperature. After completion of the reaction (TLC check) the mixture was first of all concentrated by evaporation on a rotary evaporator and then purified by column chromatography (solvent: gradient:hexane to ether:hexane=1:1)

¹H-NMR (300 MHz, CDCl₃): δ=1.38-1.77 (m, 6H); 3.08-3.35 (m, 3H); 3.41-3.53 (m, 2H); 3.61-3.73 (m, 1H); 4.50 (dd, 1H, J=8.29 Hz, J=6.03 Hz); 7.19-7.34 (m, 4H).

Synthesis of the Aldehydes

The aldehydes 15a-e and 16a-e were obtained in the way described below in a multi-stage synthesis from the commercially obtainable 4-oxo-cyclohexane-carboxylic acid ethyl ester. The yields of the prepared compounds are not optimized. All temperatures are uncorrected.

1,4-dioxa-spiro[4.5]decane-8-carboxylic acid ethyl ester 10

4-oxocyclohexane carboxylic acid ethyl ester 9 (52.8 g, 0.31 mole, Merck, Order No. 814249), ethylene glycol (67.4 g, 1.08 mol) and p-toluenesulfonic acid (0.7 g) in toluene (160 ml) were stirred for 20 hours at RT, and the reaction solution was poured into diethyl ether (300 ml) and washed with water, sodium hydrogen carbonate solution and sodium chloride solution. The solution was dried (Na₂SO₄), concentrated by evaporation in vacuo, and the remaining colorless liquid was processed further without purification.

Yield: 66.5 g (100%) ¹H-NMR (CDCl₃): 1.24 (t, 3H); 1.53 (m, 2H); 1.76 (m, 4H); 1.92 (m, 2H); 2.31 (m, 1H); 3.91 (s, 4H); 4.11 (q, 2H). ¹³C-NMR (CDCl₃): 14.28 (q); 26.32 (t); 33.76 (t); 41.59 (d); 60.14 (t); 64.21 (t); 107.90 (d); 174.77 (s).

1,4-dioxa-spiro[4.5]decane-8-carbaldehyde 11

Diisobutyl aluminium hydride (1.5 M solution in toluene, 102 ml, 153 mmole) was added dropwise to a solution of 1,4-dioxa-spiro[4.5]decane-8-carboxylic acid ethyl ester 10 (32.13 g, 150 mmole) in absolute toluene (160 ml) under argon at −70° to −65° C. and stirred for 30 minutes. The reaction mixture was then quenched at −70° to −60° C. by adding methanol (80 ml). The reaction solution was heated to RT, sodium chloride solution (100 ml) was added, and the reaction solution was suction filtered through diatomaceous earth. The diatomaceous earth was washed twice with ethyl acetate, and the aqueous solution was separated and extracted twice with ethyl acetate. The combined organic extracts were washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated by evaporation in vacuo.

Yield: 24.01 g (94%), yellow oil ¹H-NMR (CDCl₃): 1.54 (m, 2H); 1.74 (m, 4H); 1.91 (m, 2H); 2.21 (m, 1H); 3.91 (s, 4H); 9.60 (s, 1H). ¹³C-NMR (CDCl₃): 23.35 (t); 33.37 (t); 48.18 (d); 64.30 (t); 107.89 (d); 203.51 (s).

Dimethylamino-(1,4-dioxa-spiro[4.5]dec-8-yl)-acetonitrile 12

40% aqueous dimethylamine solution (85 ml, 0.67 mole), 1,4-dioxa-spiro-[4.5]decane-8-carbaldehyde 11 (240 g, 0.141 mole) and potassium cyanide (22.05 g, 0.338 mole) were added dropwise to a mixture of 4N hydrochloric acid (37 ml) and methanol (22 ml) while cooling with ice. The mixture was stirred for 4 days at room temperature and was then extracted with diethyl ether (4×100 ml) after adding water (80 ml). The organic phase was dried over sodium sulfate, concentrated by evaporation in vacuo, and the product was obtained as a white solid.

Yield: 25.2 g (81%) m.p.: 48-51° C. ¹H-NMR (CDCl₃): 1.23-2.03 (m, 9H); 2.28 (s, 6H); 3.16 (d, 1H); 3.93 (m, 4H). ¹³C-NMR (CDCl₃): 26.67 (t); 27.93 (t); 33.87 (t); 36.94 (d); 41.90 (q); 64.30 (t); 64.36 (t); 108.33 (d); 115.94 (s).

[(1,4-dioxa-spiro[4.5]dec-8-yl)-4-fluorophenylmethyl]-dimethylamine 13a (R²=4-fluorophenyl)

A solution of the aminonitrile 12 (19.89 g, 88 mmole) in absolute THF (160 ml) was added dropwise to a 1M solution of 4-fluorophenyl magnesium bromide in THF (220 ml, 220 mmole) under argon and while cooling with ice, and stirred for 20 hours at RT. To work up the reaction mixture saturated ammonium chloride solution (100 ml) and water (100 ml) were added while cooling with ice and the mixture was extracted with diethyl ether (3×100 ml). The organic phase was washed with water and saturated sodium chloride solution, dried (Na₂SO₄) and concentrated by evaporation.

Yield: 31 g (>100%) ¹³C-NMR (CDCl₃): 26.68 (t); 28.11 (t); 34.43 (t); 34.55 (t); 37.37 (d); 41.68 (q); 64.12 (t); 73.65 (d); 108.88 (d); 114.23 (d); 114.44 (d); 130.27; 130.35; 132.43; 160.36 (s); 162.78 (s).

[(1,4-dioxa-spiro[4.5]dec-8-yl)-3-fluorophenylmethyl]-dimethylamine 13b (R²=3-fluorophenyl)

A solution of the aminonitrile 12 (23.45 g, 104 mmole) in absolute THF (100 ml) was added dropwise to a 1M solution of 3-fluorophenyl magnesium bromide in THF (208 ml, 208 mmole) under argon and while cooling with ice, and stirred for 20 hours at RT. To work up the reaction mixture saturated ammonium chloride solution (100 ml) and water (100 ml) were added while cooling with ice and the mixture was extracted with diethyl ether (3×100 ml). The organic phase was washed with water and saturated sodium chloride solution, dried and concentrated by evaporation.

Yield: 30.33 g (99%). ¹H-NMR (CDCl₃): 1.12 (m, 1H); 1.26 (m, 1H); 1.46-1.81 (m, 7H); 2.10 (s, 6H); 3.10 (d, 1H); 3.90 (m, 4H); 6.85 (m, 3H); 7.27 (m, 1H). ¹³C-NMR (CDCl₃): 26.80 (t); 28.08 (t); 34.48 (t); 34.45 (t); 34.59 (t); 37.26 (d); 41.71 (q); 64.19 (t); 74.04 (t); 108.91 (d); 113.51 (d); 113.71 (d); 115.52 (d); 115.72 (d); 124.83 (d); 128.82 (d); 128.90 (d); 139.66 (s); 161.15 (s); 163.58 (s).

[(4-chlorophenyl)-(1,4-dioxa-spiro[4.5]dec-8-yl)-methyl]-dimethylamine 13c (R²=4-chlorophenyl)

A solution of the aminonitrile 12 (22.43 g, 100 mmole) in absolute ether (100 ml) was added dropwise to a 1M solution of 4-chlorophenyl magnesium bromide in ether (200 ml, 200 mmole) and stirred for 20 hours at RT. To work up the reaction mixture saturated ammonium chloride solution (100 ml) and water (100 ml) were added while cooling with ice and the mixture was extracted with diethyl ether (3×100 ml). The organic phase was washed with water and saturated sodium chloride solution, dried, and concentrated by evaporation.

Yield: 30.9 g (100%) ¹³C-NMR (CDCl₃): 26.65 (t); 28.11 (t); 34.46 (t); 34.60 (t); 37.28 (d); 41.76 (q); 64.17 (t); 73.80 (d); 108.88 (s); 127.72 (d); 129.53 (d); 132.39 (d); 135.33 (d).

[(1,4-Dioxa-spiro[4.5]dec-8-yl)-thiophen-2-yl-methyl]-dimethylamine 13d (R²=2-thienyl)

A solution of the aminonitrile 12 (2.24 g, 10 mmole) in absolute THF (10 ml) was added dropwise to a 1M solution of thiophen-2-yl-magnesium bromide in THF (20 ml, 20 mmole) under argon and while cooling with ice, and stirred for 20 hours at RT. To work up the reaction mixture saturated ammonium chloride solution (10 ml) and water (10 ml) were added while cooling with ice and the mixture was extracted with diethyl ether (3×10 ml). The organic phase was washed with water and saturated sodium chloride solution, dried and concentrated by evaporation.

Yield: 2.8 g (100%) ¹³C-NMR (CDCl₃): 27.72 (t); 27.88 (t); 34.27 (t); 39.28 (d); 41.10 (q); 64.11 (t); 68.89 (d); 108.88 (s); 123.55 (d); 125.88 (d); 127.53 (d); 139.50 (s).

[1-(1,4-dioxa-spiro[4.5]dec-8-yl)-3-phenylpropyl]-dimethylamine 13e (R²=phenethyl)

A solution of the aminonitrile 12 (21.93 g, 97 mmole) in absolute THF (180 ml) was added dropwise to a 1M solution of phenylethyl magnesium chloride in THF (242 ml, 242 mmole) under argon and while cooling with ice, and stirred for 20 hours at RT. To work up the reaction mixture saturated ammonium chloride solution (100 ml) and water (100 ml) were added while cooling with ice and the mixture was extracted with diethyl ether (3×100 ml). The organic phase was washed with water and saturated sodium chloride solution, dried, and concentrated by evaporation.

Yield: 34 g (>100%). ¹³C-NMR (CDCl₃): 27.43 (t); 28.95 (t); 29.42 (t); 34.82 (t); 35.40 (t); 38.76 (d); 41.16 (q); 64.17 (t); 67.41 (d); 108.86 (s); 125.41 (d); 127.66 (d); 128.11 (d); 142.69 (s).

4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexanone 14a (R²=4-fluorophenyl)

The crude product of the ketal 13a (26 g, 88 mmole) was dissolved in water (40 ml), concentrated hydrochloric acid (59 ml) was added, and the mixture was stirred for 20 hours at RT. The reaction mixture was extracted with diethyl ether (2×100 ml), the aqueous phase was made alkaline with 5 N NaOH while cooling in ice, extracted with dichloromethane (3×100 ml), dried, and concentrated by evaporation.

Yield: 21.36 g (98%) ¹³C-NMR (CDCl₃): 28.90 (t); 30.48 (t); 37.00 (t); 40.49 (t); 40.72 (t); 41.79 (q); 72.98 (d); 114.42 (d); 114.62 (d); 130.20 (d); 130.28 (d); 131.88 (s); 160.50 (s); 162.93 (s); 211.44 (s).

4-[dimethylamino-(3-fluorophenyl)-methyl]-cyclohexanone 14b (R²=3-fluorophenyl)

The ketal 13b (30.3 g, 103 mmole) was dissolved in water (44 ml), concentrated hydrochloric acid (64 ml) was added, and the mixture was stirred for 20 hours at RT. The reaction mixture was shaken with diethyl ether (2×100 ml), the aqueous phase was made alkaline with 5 N NaOH while cooling with ice, extracted with dichloromethane (3×100 ml), dried, and concentrated by evaporation. The ketone was isolated as a colorless solid.

Yield: 22.4 g (87%) m.p.: 72°-75° C. ¹³C-NMR (CDCl₃): 28.97 (t); 30.44 (t); 36.90 (t); 40.52 (t); 40.75 (t); 41.82 (q); 73.37 (d); 113.84; 114.06; 115.42; 115.62; 124.71; 129.03; 129.11; 139.00; 139.06; 161.16; 163.60; 211.40 (s).

4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexanone 14c (R²=4-chlorophenyl)

The ketal 13c (30.98 g, 100 mmole) was dissolved in water (44 ml), concentrated hydrochloric acid (64 ml) was added, and the mixture was stirred for 20 hours at RT. The reaction mixture was shaken with diethyl ether (2×100 ml), the aqueous phase was made alkaline with 5N NaOH while cooling with ice, extracted with dichloromethane (3×100 ml), dried and concentrated by evaporation. The ketone was isolated as an oil.

Yield: 21.9 g (82%) ¹³C-NMR (CDCl₃): 28.88 (t); 30.45 (t); 36.89 (t); 40.49 (t); 40.74 (t); 41.83 (q); 73.12 (d); 127.87 (d); 130.16 (d); 132.75 (d); 13470 (s); 211.35 (s).

4-(dimethylaminothiophen-2-yl-methyl)-cyclohexanone 14d (R²=2-thienyl)

The ketal 13d (2.80 g, 10 mmole) was dissolved in water (4.4 ml), concentrated hydrochloric acid (6.4 ml) was added, and the mixture was stirred for 20 hours at RT. The reaction mixture was shaken with diethyl ether (2×10 ml), the aqueous phase was made alkaline with 5N NaOH while cooling with ice, extracted with dichloromethane (3×10 ml), dried and concentrated by evaporation. The ketone 14d was isolated as an oil.

Yield: 1.79 g (75%) ¹³C-NMR (CDCl₃): 30.02 (t); 30.18 (t); 38.84 (t); 40.29 (t); 39.28 (d); 41.17 (q); 68.24 (d); 123.88 (d); 126.01 (d); 126.34 (d); 138.77 (d); 211.49 (s).

4-(1-dimethylamino-3-phenylpropyl)-cyclohexanone 14e (R²=phenethyl)

The crude product of the ketal 13e (29.6 g, 97 mmole) was dissolved in water (44 ml), concentrated hydrochloric acid (64 ml) was added, and the mixture was stirred for 20 hours at RT. The reaction mixture was shaken with diethyl ether (2×100 ml), the aqueous phase was made alkaline with 5N NaOH while cooling with ice, and extracted with dichloromethane (3×100 ml), dried and concentrated by evaporation. The ketone was isolated as a colorless oil.

Yield: 16.9 g (58%) ¹³C-NMR (CDCl₃): 29.40 (t); 30.02 (t); 30.97 (t); 35.34 (t); 38.71 (t); 40.79 (t); 41.01 (t); 41.23 (q); 66.65 (d); 125.66 (d); 128.12 (d); 128.19 (d); 142.27 (s); 211.70 (s).

4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexanecarbaldehyde 15a (R²=4-fluorophenyl)

(Methoxymethyl)triphenylphosphonium chloride (25.7 g, 75 mmole) was suspended in absolute THF (100 ml) under argon, potassium tert-butylate (8.42 g, 75 mmole), dissolved in absolute THF (70 ml), was added dropwise at 0° C., and the mixture was then stirred for 15 minutes at 0° C. The ketone 14a (12.44 g, 50 mmole), dissolved in absolute THF (75 ml), was then added dropwise at RT to the above solution and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water (38 ml) and 6N HCl (112 ml) while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted with ether (10×50 ml), and the aqueous phase was adjusted to pH 11 with 5N NaOH, shaken with ethyl acetate (3×50 ml), dried over Na₂SO₄ and concentrated by evaporation in vacuo. The crude product was purified by flash chromatography with ethyl acetate/cyclohexane (1:1).

Yield: 9.13 g (70%). ¹H-NMR (DMSO, 600 MHz, selected signals): δ=1.97 (s, 3H); 1.99 (s, 3H); 3.08 (d, 1H, J=9.06 Hz); 3.14 (d, 1H, J=9.82 Hz); 9.53 (s, 1H); 9.56 (s, 1H). ¹³C-NMR (CDCl₃, both diastereomers): δ=23.97; 24.21; 25.85; 26.02; 26.17; 27.35; 28.00; 29.90; 37.26; 38.34; 41.50; 41.95; 47.36; 50.55; 72.75; 75.84; 114.25; 114.45; 130.33; 130.40; 132.61; 160.41; 162.83; 204.10; 204.93.

4-[dimethylamino-(3-fluorophenyl)-methyl]-cyclohexanecarbaldehyde 15b (R²=3-fluorophenyl)

(Methoxymethyl)triphenylphosphonium chloride (15.42 g, 45 mmole) was suspended in absolute THF (50 ml) under argon, potassium tert-butylate (5.05 g, 45 mmole), dissolved in absolute THF (50 ml), was added dropwise at 0° C., and the mixture was then stirred for 15 minutes at 0° C. The ketone 14b (7.48 g, 0.30 mmole), dissolved in absolute THF (50 ml), was then added dropwise at RT to the above solution and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water (25 ml) and 6N HCl (75 ml) while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted with ether (10×50 ml), and the aqueous phase was adjusted to pH 11 with 5N NaOH, extracted with ethyl acetate (3×50 ml), dried over Na₂SO₄ and concentrated in vacuo. The crude product was purified by flash chromatography with ethyl acetate/cyclohexane (1:1).

Yield: 6.55 g (83%). m.p.: 40-43° C. ¹H-NMR (DMSO, 600 MHz, selected signals): δ=1.99 (s, 3H); 2.01 (s, 3H); 3.10 (d, 1H, J=9.06 Hz); 3.18 (d, 1H, J=9.82 Hz); 9.54 (s, 1H); 9.56 (s, 1H). ¹³C-NMR (CDCl₃): 23.93; 24.12; 25.79; 25.95; 26.19; 27.19; 27.99; 29.77; 37.05; 38.16; 41.45; 41.91; 47.30; 50.49; 71.50; 74.78; 113.50; 115.37; 124.78; 128.24; 130.59; 131.24; 131.67; 139.14; 139.76; 160.06; 163.50; 204.01; 204.85.

4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexanecarbaldehyde 15c (R²=4-chlorophenyl)

(Methoxymethyl)triphenylphosphonium chloride (68.55 g, 200 mmole) was suspended in absolute THF (200 ml) under argon, potassium tert-butylate (22.44 g, 200 mmole), dissolved in absolute THF (300 ml), was added dropwise at 0° C., and the mixture was then stirred for 15 minutes at 0° C. The ketone 14c (38 g, 143 mmole), dissolved in absolute THF (200 ml), was then added dropwise at RT to the above solution and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water (150 ml) and 6N HCl (450 ml) while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted with ether (10×100 ml), and the aqueous phase was adjusted to pH 11 with 5N NaOH, shaken with ethyl acetate (3×100 ml), dried over Na₂SO₄ and concentrated by evaporation in vacuo. The crude product was purified by passage through two silica gel columns (400 g) with ethyl acetate/cyclohexane (1:1).

Yield: 32.17 g (80%). ¹H-NMR (DMSO, 600 MHz, selected signals): δ=1.97 (s, 3H); 1.99 (s, 3H); 3.07 (d, 1H, J=9.07 Hz); 3.14 (d, 1H, J=9.82 Hz); 9.53 (s, 1H); 9.55 (s, 1H). ¹³C-NMR (CDCl₃ both diastereomers): δ=23.92; 24.16; 25.80; 25.97; 26.13; 27.25; 27.90; 29.81; 37.08; 38.19; 41.47; 41.96; 47.29; 50.48; 72.81; 74.54; 127.65; 130.28; 132.40; 134.78; 135.43; 203.98; 204.82.

4-(dimethylaminothiophen-2-yl-methyl)-cyclohexanecarbaldehyde 15d (R²=2-thienyl)

(Methoxymethyl)triphenylphosphonium chloride (20.56 g, 60 mmole) was suspended in absolute THF (70 ml) under argon, potassium tert-butylate (6.73 g, 60 mmole), dissolved in absolute THF (70 ml), was added dropwise at 0° C., and the mixture was then stirred for 15 minutes at 0° C. The ketone 14d (9.4 g, 40 mmole), dissolved in absolute THF (70 ml), was then added dropwise at RT to the above solution and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water, (60 ml) and 6 N HCl (180 ml) while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted with ether (5×50 ml), and the aqueous phase was adjusted to pH 11 with 5 N NaOH, shaken with ethyl acetate (3×50 ml), dried over Na₂SO₄ and concentrated by evaporation in vacuo. The crude product was purified by flash chromatography with ethyl acetate/cyclohexane (1:1).

Yield: 7.66 g (77%). ¹H-NMR (DMSO, 600 MHz, selected signals): δ=2.03 (s, 3H); 2.05 (s, 3H); 3.44 (d, 1H, J=9.82 Hz); 3.52 (d, 1H, J=10.58 Hz); 9.54 (s, 1H); 9.58 (s, 1H). ¹³C-NMR (CDCl₃, both diastereomers): δ=23.74; 23.83; 25.80; 25.84; 26.98; 27.09; 29.15; 29.68; 39.13; 40.20; 40.98; 41.29 (N(CH₃)₂); 47.48; 50.49; 67.81; 69.79; 123.61; 123.70; 125.89; 126.20; 126.24; 139.14; 139.48; 204.07; 204.82.

4-(1-dimethylamino-3-phenylpropyl)-cyclohexanecarbaldehyde 15e (R²=phenethyl)

(Methoxymethyl)triphenylphosphonium chloride (20.56 g, 60 mmole) was suspended in absolute THF (85 ml) under argon, potassium tert-butylate (6.73 g, 60 mmole), dissolved in absolute THF (70 ml), was added dropwise at 0° C., and the mixture was then stirred for 15 minutes at 0° C. The ketone 14e (10.2 g, 40 mmole), dissolved in absolute THF (60 ml), was then added dropwise at RT to the above solution and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water (35 ml) and 6N HCl (90 ml) while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted with ether (10×50 ml), and the aqueous phase was adjusted to pH 11 with 5N NaOH, extracted with ethyl acetate (3×50 ml), dried over Na₂SO₄ and concentrated by evaporation in vacuo. The crude product was purified by flash chromatography with ethyl acetate/cyclohexane (1:1).

Yield: 6.73 g (63%). ¹H-NMR (DMSO, 600 MHz, selected signals): δ=2.18 (s, 3H); 2.20 (s, 3H); 9.54 (s, 1H); 9.61 (s, 1H). ¹³C-NMR (CDCl₃, both diastereomers): δ=24.35; 24.49; 26.00; 26.09; 26.85; 27.79; 29.07; 29.13; 35.27; 39.02; 40.98; 41.19; 46.99; 50.33; 66.85; 67.85; 70.54; 71.42; 125.40; 125.44; 128.02; 128.13; 131.15; 131.17; 142.45; 204.10; 205.01.

{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-acetaldehyde 16a (R²=4-fluorophenyl)

(Methoxymethyl)triphenylphosphonium chloride (43.53 g, 127 mmole) was suspended in absolute THF (200 ml) under argon, potassium tert-butylate (14.25 g, 127 mmole), dissolved in absolute THF (130 ml), was added dropwise at 0° C., and the mixture was then stirred for 15 minutes at 0° C. The aldehyde 15a (22.3 g, 85 mmole), dissolved in absolute THF (130 ml), was then added dropwise at RT and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water (80 ml) and 6N HCl (200 ml) while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted 10 times with ether (each time 100 ml). The aqueous phase was adjusted to pH 11 with 5N NaOH, shaken three times with ethyl acetate (each time 100 ml), dried over Na₂SO₄ and concentrated by evaporation in vacuo. The crude product was purified by flash chromatography with ethyl acetate/cyclohexane (1:1).

Yield: 15.8 g (67%) ¹³C-NMR (CDCl₃, both diastereomers): δ=25.08; 25.87; 28.80; 29.10; 29.13; 29.62; 30.82; 32.90; 33.08; 36.19; 38.43; 41.36; 42.01; 47.94; 51.17; 71.11; 74.69; 114.11; 114.20; 114.32; 130.32; 130.40; 132.00; 132.92; 160.31; 162.74; 202.15; 202.23.

{4-[dimethylamino-(3-fluorophenyl)-methyl]-cyclohexyl}-acetaldehyde 16b (R²=3-fluorophenyl)

(Methoxymethyl)triphenylphosphonium chloride (26.73 g, 78 mmole) was suspended in absolute THF (90 ml) under argon, potassium tert-butylate (8.75 g, 78 mmole), dissolved in absolute THF (90 ml), was added dropwise at 0° C., and the mixture was then stirred for 15 minutes at 0° C. The aldehyde 15b (13.69 g, 52 mmole), dissolved in absolute THF (90 ml), was then added dropwise at RT and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water (50 ml) and 6N HCl (150 ml), while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted 10 times with ether (each time 50 ml). The aqueous phase was adjusted to pH 11 with 5N NaOH, shaken three times with ethyl acetate (each time 100 ml), dried over Na₂SO₄ and concentrated by evaporation in vacuo. The crude product was purified by flash chromatography with ethyl acetate/cyclohexane (1:1).

Yield: 12.61 g (87%) ¹³C-NMR (CDCl₃, both diastereomers): δ=25.19; 25.83; 28.90; 29.06; 29.14; 29.68; 30.77; 32.92; 32.98; 33.10; 36.05; 38.36; 41.39; 42.04; 48.02; 51.20; 71.48; 75.07; 113.43; 113.49; 113.64; 113.69; 115.55; 115.76; 124.89; 128.70; 128.78; 128.88; 139.24; 140.08; 140.14; 161.09; 163.52; 202.19; 202.27.

{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-acetaldehyde 16c (R²=4-chlorophenyl)

(Methoxymethyl)triphenylphosphonium chloride (25.02 g, 73 mmole) was suspended in absolute THF (90 ml) under argon, potassium tert-butylate (8.19 g, 73 mmole), dissolved in absolute THF (90 ml), was added dropwise at 0° C., and the mixture was then stirred for 15 minutes at 0° C. The aldehyde 15c (13.86 g, 49 mmole), dissolved in absolute THF (90 ml), was then added dropwise at RT and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water (50 ml) and 6N HCl (150 ml) while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted ten times with ether (each time 50 ml). The aqueous phase was adjusted to pH 11 with 5N NaOH, shaken three times with ethyl acetate (each time 100 ml), dried over Na₂SO₄ and concentrated by evaporation in vacuo. The crude product was purified by flash chromatography with ethyl acetate/cyclohexane (1:1).

Yield: 12.07 g (84%). ¹³C-NMR (CDCl₃, both diastereomers): δ=25.06; 25.82; 28.74; 29.00; 29.13; 29.60; 30.77; 32.87; 32.94; 33.07; 36.06; 38.32; 41.38; 42.05; 47.95; 51.17; 71.23; 74.80; 127.58; 127.66; 130.31; 132.28; 132.34; 134.81; 135.77; 202.12; 202.20.

{4-[dimethylaminothiophen-2-yl-methyl]-cyclohexyl}-acetaldehyde 16d (R²=2-thienyl)

(Methoxymethyl)triphenylphosphonium chloride (28.79 g, 84 mmole) was suspended in absolute THF (100 ml) under argon, potassium tert-butylate (9.42 g, 84 mmole), dissolved in absolute THF (100 ml), was added dropwise at 0° C., and the mixture was then stirred for 15 min at 0° C. The aldehyde 15d (14.08 g, 56 mmole), dissolved in absolute THF (100 ml), was then added dropwise at RT and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water (50 ml) and 6N HCl (150 ml) while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted ten times with ether (each time 50 ml). The aqueous phase was adjusted to pH 11 with 5N NaOH, shaken with three times with ethyl acetate (each time 100 ml), dried over Na₂SO₄ and concentrated by evaporation in vacuo. The crude product was purified by flash chromatography with ethyl acetate/cyclohexane (1:2).

Yield: 11.48 g (77%). ¹³C-NMR (CDCl₃, both diastereomers): δ=25.80; 25.88; 28.73; 29.95; 30.49, 32.23; 32.76; 37.89; 40.21; 40.88; 41.23; 48.36; 51.09; 66.02; 69.97; 123.19; 123.72; 125.95; 126.31; 139.42; 139.91; 202.61.

[4-(1-dimethylamino-3-phenylpropyl)-cyclohexyl]-acetaldehyde 16e (R²-phenethyl)

(Methoxymethyl)triphenylphosphonium chloride (50.3 g, 147 mmole) was suspended in absolute THF (150 ml) under argon, potassium tert-butylate (16.5 g, 147 mmole), dissolved in absolute THF (140 ml), was added dropwise at 0° C. and the mixture was then stirred for 15 minutes at 0° C. The aldehyde 15e (27.0 g, 98 mmole), dissolved in absolute THF (150 ml), was then added dropwise at RT and the mixture was stirred overnight at RT. The mixture was hydrolysed by dropwise addition of water (102 ml) and 6N HCl (240 ml) while cooling in iced water. After stirring for 1 hour at RT the mixture was extracted five times with ether (each time 200 ml). The aqueous phase was adjusted to pH 11 with 5N NaOH while cooling with ice, shaken three times with ethyl acetate (each time 200 ml), dried over Na₂SO₄ and concentrated by evaporation in vacuo. The crude product was purified by flash chromatography with ethyl acetate/cyclohexane (1:1).

Yield: 18.1 g (64%) ¹³C-NMR (CDCl₃, both diastereomers): δ=25.55; 26.19; 29.04; 29.15; 29.35; 29.85; 31.00; 32.87; 32.68; 33.04; 35.33; 38.49; 40.86; 41.13; 47.51; 51.15; 65.48; 68.09; 125.58; 128.20; 142.79; 202.69.

Automated Synthesis

The compounds were prepared with the aid of the automated synthesis protocol using the SLT106 accelerator from the company Chemspeed Ltd according to the following experimental procedure:

120 μmole (1.2 ml, 0.1 M in methanol) of aldehyde solution (solution II), 130 μmole (1.3 ml, 0.1 M in methanol) of amine solution (solution III) and 100 μmole (1 ml, 0.1 M in methanol) of isonitrile amide derivative (solution I) were added at room temperature to a dry 13 ml capacity double jacket glass reactor. The reaction solution was heated for 6 hours at 60° C. and shaken. After completion of the reaction, the reaction solution was concentrated by evaporation in a GeneVac. Purification was carried out by HPLC.

The following compounds were prepared by the general procedure described above. The analysis was carried out by HPLC-MS. In all cases the exact mass was found as M+1.

No. Name Mass 17. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-piperidin-1-yl-methyl]- 558.37 cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine 18. ((4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-{4-[dimethylamino-(4- 596.35 fluorophenyl)-methyl]-cyclohexyl}-methyl)-methylphenylamine 19. ([4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-{4-[dimethylamino-(4- 608.39 fluorophenyl)-methyl]-cyclohexyl}-methyl)-methylphenylamine 20. ([4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-{4-[(4-chlorophenyl)- 590.38 dimethylaminomethyl]-cyclohexyl}-methyl)-diethylamine 21. Benzyl-[4-benzyl-2-({4-[(4-chlorophenyl)-dimethylaminomethyl]- 612.36 cyclohexyl}-diethylaminomethyl)-oxazol-5-yl]-methylamine 22. Benzyl-{4-benzyl-2-[{4-[(4-chlorophenyl)-dimethylaminomethyl]- 646.34 cyclohexyl}-(methylphenylamine)-methyl]-oxazol-5-yl}-methylamine 23. [(4-{[4-benzyl-5-(4-benzyl-piperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}- 650.40 cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 24. [(4-{[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}- 574.37 cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 25. Benzyl-(4-benzyl-2-{[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]- 596.35 piperidin-1-yl-methyl}-oxazol-5-yl)-methylamine 26. [(4-{[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}- 637.38 cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 27. {[4-benzyl-5-(4-benzyl-piperidin-1-yl)-oxazol-2-yl]-[4-(dimethylamino- 638.40 thiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine 28. {[4-benzyl-5-(4-benzyl-piperazin-1-yl)-oxazol-2-yl]-[4-(dimethylamino- 639.40 thiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine 29. {[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-[4-(dimethylamino- 562.37 thiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine 30. Benzyl-(4-benzyl-2-{diethylamino-[4-(dimethylaminothiophen-2-yl-methyl)- 584.35 cyclohexyl]-methyl}-oxazol-5-yl)-methylamine 31. {[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-[4-(dimethylamino- 625.38 thiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine 32. ({4-[[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-(4-benzylpiperazin-1- 741.44 yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 33. [(4-{[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}- 586.40 cyclohexyl)-(4-fluorophenyl)-methyl]-dimethylamine 34. [4-benzyl-2-(diethylamino-{4-[dimethylamino-(4-fluorophenyl)-methyl]- 610.40 cyclohexyl}-methyl)-oxazol-5-yl]-methylphenethylamine 35. [4-benzyl-2-(diethylamino-{4-[dimethylamino-(4-fluorophenyl)-methyl]- 548.39 cyclohexyl}-methyl)-oxazol-5-yl]-diethylamine 36. ([4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-{4-[dimethylamino-(4- 574.40 fluorophenyl)-methyl]-cyclohexyl}-methyl)-diethylamine 37. ([4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-{4-[dimethylamino-(4- 622.40 fluorophenyl)-methyl]-cyclohexyl}-methyl)-methylphenylamine 38. {4-benzyl-2-[{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}- 644.39 (methylphenylamine)-methyl]-oxazol-5-yl}-methylphenethylamine 39. [4-benzyl-2-({4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}- 576.36 piperidin-1-yl-methyl)-oxazol-5-yl]-diethylamine 40. [(4-{[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}- 602.38 cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine 41. ([4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-{4-[(4-chlorophenyl)- 604.39 dimethylaminomethyl]-cyclohexyl}-methyl)-diethylamine 42. ([4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-{4-[(4-chlorophenyl)- 638.38 dimethylaminomethyl]-cyclohexyl}-methyl)-methylphenylamine 43. {4-benzyl-2-[{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}- 660.36 (methylphenylamine)-methyl]-oxazol-5-yl}-methylphenethylamine 44. [4-benzyl-2-((4-benzylpiperazin-1-yl)-{4-[(4-chlorophenyl)- 667.40 dimethylaminomethyl]-cyclohexyl}-methyl)-oxazol-5-yl]-diethylamine 45. [(4-{[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl- 588.39 methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 46. (4-benzyl-2-{[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-piperidin- 610.37 1-yl-methyl}-oxazol-5-yl)-methylphenethylamine 47. (4-benzyl-2-{[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-piperidin- 548.35 1-yl-methyl}-oxazol-5-yl)-diethylamine 48. ({4-[(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-piperidin-1-yl-methyl]- 578.31 cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 49. (4-benzyl-2-{diethylamino-[4-(dimethylamino-thiophen-2-yl-methyl)- 598.37 cyclohexyl]-methyl}-oxazol-5-yl)-methylphenethylamine 50. (4-benzyl-2-{diethylamino-[4-(dimethylaminothiophen-2-yl-methyl)- 536.35 cyclohexyl]-methyl}-oxazol-5-yl)-diethylamine 51. {[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-[4-(dimethylamino- 562.37 thiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine 52. {(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-[4-(dimethylaminothiophen-2- 600.30 yl-methyl)-cyclohexyl]-methyl}-methylphenylamine 53. ({4-[[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-(4-benzyl- 679.43 piperazin-1-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 54. (4-benzyl-2-{(4-benzyl-piperazin-1-yl)-[4-(dimethylaminothiophen-2-yl- 701.41 methyl)-cyclohexyl]-methyl}-oxazol-5-yl)-methyl-phenethylamine 55. ({4-[(4-benzylpiperazin-1-yl)-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)- 669.35 methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 56. [(4-{2-[4-benzyl-5-(4-benzyl-piperazin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl- 693.42 ethyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine 57. [(4-{2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl- 616.39 ethyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine 58. Benzyl-[4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]- 638.38 cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylamine 59. (1-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[(4-chlorophenyl)- 680.42 dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine 60. (1-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[(4-chlorophenyl)- 604.39 dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine 61. Benzyl-[4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]- 626.38 cyclohexyl}-1-diethylamino-ethyl)-oxazol-5-yl]-methylamine 62. [{4-[2-[4-benzyl-5-(4-benzyl-piperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 783.46 piperazin-1-yl)-ethyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine 63. [{4-[2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 784.46 piperazin-1-yl)-ethyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine 64. [{4-[2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 707.43 piperazin-1-yl)-ethyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine 65. [(4-{2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl- 600.42 ethyl}-cyclohexyl)-(4-fluorophenyl)-methyl]-dimethylamine 66. Benzyl-[4-benzyl-2-(2-{4-[dimethylamino-(4-fluorophenyl)-methyl]- 622.40 cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylamine 67. (1-[4-benzyl-5-(4-benzyl-piperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4- 664.45 fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine 68. (1-[4-benzyl-5-(4-benzyl-piperazin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino- 665.45 (4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine 69. (1-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4- 588.42 fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine 70. Benzyl-[4-benzyl-2-(1-diethylamino-2-{4-[dimethylamino-(4-fluorophenyl)- 610.40 methyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-methylamine 71. [{4-[2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 691.46 piperazin-1-yl)-ethyl]-cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine 72. [(4-{2-[4-benzyl-5-(4-benzyl-piperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl- 664.42 ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 73. [(4-{2-[4-benzyl-5-(4-benzyl-piperazin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl- 665.41 ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 74. [(4-{2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl- 588.39 ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 75. Benzyl-(4-benzyl-2-{2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]- 610.37 1-piperidin-1-yl-ethyl}-oxazol-5-yl)-methylamine 76. [(4-{2-[4-benzyl-5-(4-phenyl-piperazin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl- 651.40 ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 77. {1-[4-benzyl-5-(4-benzyl-piperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino- 652.42 thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine 78. {1-[4-benzyl-5-(4-benzyl-piperazin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino- 653.41 thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine 79. {1-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino- 576.39 thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine 80. Benzyl-(4-benzyl-2-{1-diethylamino-2-[4-(dimethylaminothiophen-2-yl- 598.37 methyl)-cyclohexyl]-ethyl)-oxazol-5-yl)-methylamine 81. ({4-[2-[4-benzyl-5-(4-benzyl-piperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 755.46 piperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 82. ({4-[2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 756.45 piperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 83. ({4-[2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 679.43 piperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 84. Benzyl-(4-benzyl-2-{1-(4-benzyl-piperazin-1-yl)-2-[4-(dimethylamino- 701.41 thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-oxazol-5-yl)-methylamine 85. ({4-[2-[4-benzyl-5-(4-phenyl-piperazin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 742.44 piperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 86. [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1- 652.39 piperidin-1-yl-ethyl)-oxazol-5-yl]-methylphenethylamine 87. [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1- 590.38 piperidin-1-yl-ethyl)-oxazol-5-yl]-diethylamine 88. (1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[(4- 618.41 chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine 89. [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1- 640.39 diethylaminoethyl)-oxazol-5-yl]-methyl-phenethylamine 90. [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1- 578.38 diethylaminoethyl)-oxazol-5-yl]-diethylamine 91. (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[(4-chlorophenyl)- 608.33 dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine 92. (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[(4-chlorophenyl)- 642.32 dimethylaminomethyl]-cyclohexyl}-ethyl)-methylphenylamine 93. [4-Benzyl-2-(1-(4-benzylpiperazin-1-yl)-2-{4-[(4-chlorophenyl)- 743.43 dimethylaminomethyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-methylphenethyl- amine 94. [4-benzyl-2-(1-(4-benzylpiperazin-1-yl)-2-{4-[(4-chlorophenyl)- 681.42 dimethylaminomethyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-diethylamine 95. [4-benzyl-2-(2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1- 636.42 piperidin-1-yl-ethyl)-oxazol-5-yl]-methylphenethylamine 96. (1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-{4- 602.44 [dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine 97. [4-benzyl-2-(1-diethylamino-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]- 624.42 cyclohexyl}-ethyl)-oxazol-5-yl]-methylphenethylamine 98. [4-benzyl-2-(1-diethylamino-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]- 562.40 cyclohexyl}-ethyl)-oxazol-5-yl]-diethylamine 99. (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[dimethylamino-(4- 592.36 fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine 100. (1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4- 588.42 fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine 101. (1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-{4- 636.42 [dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)- methylphenylamine 102. {4-benzyl-2-[2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1- 658.40 (methylphenylamine)-ethyl]-oxazol-5-yl}-methylphenethylamine 103. {4-benzyl-2-[2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1- 596.39 (methylphenylamine)-ethyl]-oxazol-5-yl}-diethylamine 104. (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[dimethylamino-(4- 626.35 fluorophenyl)-methyl]-cyclohexyl}-ethyl)-methylphenylamine 105. (1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4- 622.40 fluorophenyl)-methyl]-cyclohexyl}-ethyl)-methylphenylamine 106. [{4-[2-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 691.46 piperazin-1-yl)-ethyl]-cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine 107. [(4-{2-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl- 602.40 ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 108. (4-benzyl-2-{2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-1- 624.39 piperidin-1-yl-ethyl}-oxazol-5-yl)-methylphenethylamine 109. (4-benzyl-2-{2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-1- 562.37 piperidin-1-yl-ethyl}-oxazol-5-yl)-diethylamine 110. ({4-[2-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-piperidin-1-yl-ethyl]- 592.33 cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 111. [(4-{2-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl- 588.39 ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 112. {1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-[4- 590.40 (dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine 113. (4-benzyl-2-{1-diethylamino-2-[4-(dimethylaminothiophen-2-yl-methyl)- 612.39 cyclohexyl]-ethyl}-oxazol-5-yl)-methylphenethylamine 114. (4-benzyl-2-{1-diethylamino-2-[4-(dimethylaminothiophen-2-yl-methyl)- 550.37 cyclohexyl]-ethyl}-oxazol-5-yl)-diethylamine 115. {1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-[4-(dimethylamino- 580.33 thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine 116. {1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino- 576.39 thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine 117. {1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino- 610.37 thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-methylphenylamine 118. ({4-[2-(4-benzylpiperazin-1-yl)-2-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2- 683.37 yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 119. ({4-[2-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl- 679.43 piperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 120. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-morpholin-4-yl-methyl]- 560.35 cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine 121. [{4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-morpholin-4-yl-methyl]- 576.35 cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine 122. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-fluorophenyl)-piperazin-1- 653.39 yl]-methyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine 123. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin- 665.41 1-yl]-methyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine 124. [(4-{(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)- 681.41 piperazin-1-yl]-methyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine 125. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2- 606.37 yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine 126. [{4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2- 622.37 yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine 127. [{4-[{4-benzyl-5-[4-(4-methoxy-phenyl)-piperazin-1-yl]-oxazol-2-yl}-(3,4- 727.43 dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]- dimethylamine 128. [{4-[[4-benzyl-5-(2,6-dimethyl-morpholin-4-yl)-oxazol-2-yl]-(3,4-dihydro-1H- 650.40 isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]- dimethylamine 129. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-morpholin-4-yl-methyl]- 576.32 cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine 130. [{4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-morpholin-4-yl-methyl]- 592.32 cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine 131. [[4-({4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}- 697.38 morpholin-4-yl-methyl)-cyclohexyl]-(4-chlorophenyl)-methyl]-dimethylamine 132. [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-morpholin-4-yl- 620.35 methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine 133. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-fluorophenyl)-piperazin-1- 669.36 yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine 134. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin- 681.38 1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine 135. [(4-{(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)- 697.38 piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine 136. [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-[4-(4-methoxy- 725.41 phenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]- dimethylamine 137. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2- 622.34 yl)-methyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine 138. ({4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-morpholin-4-yl-methyl]- 548.32 cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 139. ({4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-morpholin-4-yl-methyl]- 564.31 cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 140. {[4-({4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}- 669.37 morpholin-4-yl-methyl)-cyclohexyl]-thiophen-2-yl-methyl}-dimethylamine 141. [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-morpholin-4-yl- 592.34 methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 142. [(4.-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-fluorophenyl)-piperazin-1- 641.36 yl]-me.thyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 143. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin- 653.38 1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 144. [(4-{(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-[4-(4-methoxy-phenyl)- 669.37 piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 145. [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-[4-(4-methoxy- 697.40 phenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]- dimethylamine 146. ({4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2- 594.34 yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 147. ({4-[{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-(3,4- 715.39 dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)- dimethylamine 148. ({4-[[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-(3,4-dihydro-1H- 638.37 isoquinolin-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 149. [{4-[2-(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-2-morpholin-4-yl-ethyl]- 574.37 cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine 150. [{4-[2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-morpholin-4-yl-ethyl]- 590.36 cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine 151. [[4-(2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2- 695.42 morpholin-4-yl-ethyl)-cyclohexyl]-(3-fluorophenyl)-methyl]-dimethylamine 152. [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-morpholin-4- 618.39 yl-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine 153. [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-[4-(4- 711.43 fluorophenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]- dimethylamine 154. [(4-{2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-[4-(4-methoxy-phenyl)- 695.42 piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine 155. [(4-{2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-[4- 800.48 (4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)- methyl]-dimethylamine 156. [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-[4-(4- 723.45 methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]- dimethylamine 157. [{4-[2-{4-benzyl-5-[4-(4-methoxy-phenyl)-piperazin-1-yl]-oxazol-2-yl}-2-(3,4- 741.44 dihydro-1H-isoquinolin-2-yl)-ethyl]-cyclohexyl}-(3-fluorophenyl)-methyl]- dimethylamine 158. ({4-[2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-morpholin-4-yl-ethyl]- 578.33 cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine 159. {[4-(2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2- 683.39 morpholin-4-yl-ethyl)-cyclohexyl]-thiophen-2-yl-methyl}-dimethylamine 160. [(4-{2-[4-benzyl-5-(2,6-dimethyl-morpholin-4-yl)-oxazol-2-yl]-2-morpholin-4- 606.36 yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 161. [(4-{2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-[4-(4-fluorophenyl)- 671.37 piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 162. [(4-{2-{4-benzyl-5-[4-(4-methoxy-phenyl)-piperazin-1-yl]-oxazol-2-yl}-2-[4- 776.42 (4-fluorophenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]- dimethylamine 163. [(4-{2-(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-2-[4-(4-methoxyphenyl)- 667.39 piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine 164. [(4-{2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-[4- 788.44 (4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]- dimethylamine 165. [(4-{2-[4-benzyl-5-(2,6-dimethyl-morpholin-4-yl)-oxazol-2-yl]-2-[4-(4- 711.42 methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]- dimethylamine 166. ({4-[2-{4-benzyl-5-[4-(4-methoxy-phenyl)-piperazin-1-yl]-oxazol-2-yl}-2- 729.41 (3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)- dimethylamine Investigations on the Efficacy of the Compounds According to the Invention

The data obtained in the following assays are summarized in Table 1.

Method for Determining the Affinity for the Human μ-Opiate Receptor

The receptor affinity for the human μ-opiate receptor is determined in a homogeneous batch in microtiter plates. For this purpose dilution series of the substances to be tested are incubated for 90 minutes at room temperature with a receptor membrane preparation (15-40 μg protein/250 μl incubation batch) of CHO-K1 cells, which express the human μ-opiate receptor (RB-HOM receptor membrane preparation from the Nen company, Zaventem, Belgium), in the presence of 1 nmole/l of the radioactive ligand [³H]-naloxone (NET719, Nen company, Zaventem, Belgium) and 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 μl. 50 mmole/l of Tris-HCl supplemented with 0.05% sodium azide and with 0.06% bovine serum albumin is used as incubation buffer. In order to determine the non-specific binding, 25 μmole/l of naloxone is additionally added. After the end of the 90 minutes' incubation time the microtiter plates are centrifuged for 20 minutes at 1000 g and the radioactivity is measured in a beta counter (Microbeta-Trilux, PerkinElmer Wallac, Freiburg, Germany). The percentage displacement of the radioactive ligand from its binding to the human μ-opiate receptor at a concentration of the test substances of 1 μmole/l is determined and is given as percentage inhibition of the specific binding.

μ-opioid receptor, % inhibition n R² R³ R⁴ R¹ R⁷ R⁸ [1 μM] 17 0

]—(CH₂)₅—[ CH₂Ph ]—(CH₂)₄—[ 76 18 0

Me Ph CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 65 19 0

Me Ph CH₂Ph

63 20 0

Et Et CH₂Ph

63 21 0

Et Et CH₂Ph Me CH₂Ph 72 22 0

Me CH₂Ph CH₂Ph Me CH₂Ph 64 23 0

]—(CH₂)₅—[ CH₂Ph

70 24 0

]—(CH₂)₅—[ CH₂Ph

70 25 0

]—(CH₂)₅—[ CH₂Ph Me CH₂Ph 80 26 0

]—(CH₂)₅—[ CH₂Ph

85 27 0

Et Et CH₂Ph

78 28 0

Et Et CH₂Ph

72 29 0

Et Et CH₂Ph

95 30 0

Et Et CH₂Ph Me CH₂Ph 92 31 0

Et Et CH₂Ph

62 32 0

CH₂Ph

75 33 0

]—(CH₂)₅—[ CH₂Ph

65 34 0

Et Et CH₂Ph Me (CH₂)₂Ph 84 35 0

Et Et CH₂Ph Et Et 61 36 0

Et Et CH₂Ph

69 37 0

Me Ph CH₂Ph

68 38 0

Me Ph CH₂Ph Me (CH₂)₂Ph 62 39 0

]—(CH₂)₅—[ CH₂Ph Et Et 75 40 0

]—(CH₂)₅—[ CH₂Ph

60 41 0

Et Et CH₂Ph

64 42 0

Me Ph CH₂Ph

79 43 0

Me Ph CH₂Ph Me (CH₂)₂Ph 72 44 0

CH₂Ph Et Et 67 45 0

]—(CH₂)₅—[ CH₂Ph

71 46 0

]—(CH₂)₅—[ CH₂Ph Me (CH₂)₂Ph 80 47 0

]—(CH₂)₅—[ CH₂Ph Et Et 73 48 0

]—(CH₂)₅—[ CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 60 49 0

Et Et CH₂Ph Me (CH₂)₂Ph 90 50 0

Et Et Ch₂Ph Et Et 83 51 0

Et Et CH₂Ph

100 52 0

Me Ph CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 92 53 0

CH₂Ph

86 54 0

CH₂Ph Me (CH₂)₂Ph 74 55 0

CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 63 56 1

]—(CH₂)₅—[ CH₂Ph

62 57 1

]—(CH₂)₅—[ CH₂Ph

64 58 1

]—(CH₂)₅—[ CH₂Ph Me CH₂Ph 73 59 1

Et Et CH₂Ph

60 60 1

Et Et CH₂Ph

68 61 1

Et Et CH₂Ph Me CH₂Ph 76 62 1

CH₂Ph

87 63 1

CH₂Ph

78 64 1

CH₂Ph

69 65 1

]—(CH₂)₅—[ CH₂Ph

61 66 1

]—(CH₂)₅—[ CH₂Ph Me CH₂Ph 65 67 1

Et Et CH₂Ph

64 68 1

Et Et CH₂Ph

60 69 1

Et Et CH₂Ph

82 70 1

Et Et CH₂Ph Me CH₂Ph 60 71 1

CH₂Ph

67 72 1

]—(CH₂)₅—[ CH₂Ph

69 73 1

]—(CH₂)₅—[ CH₂Ph

94 74 1

]—(CH₂)₅—[ CH₂Ph

79 75 1

]—(CH₂)₅—[ CH₂Ph Me CH₂Ph 90 76 1

]—(CH₂)₅—[ CH₂Ph

94 77 1

Et Et CH₂Ph

91 78 1

Et Et CH₂Ph

100 79 1

Et Et CH₂Ph

97 80 1

Et Et CH₂Ph Me CH₂Ph 93 81 1

CH₂Ph

81 82 1

CH₂Ph

83 83 1

CH₂Ph

97 84 1

CH₂Ph Me CH₂Ph 88 85 1

CH₂Ph

91 86 1

]—(CH₂)₅—[ CH₂Ph Me (CH₂)₂Ph 63 87 1

]—(CH₂)₅—[ CH₂Ph Et Et 64 88 1

Et Et CH₂Ph

79 89 1

Et Et CH₂Ph Me (CH₂)₂Ph 87 90 1

Et Et CH₂Ph Et Et 89 91 1

Et Et CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 75 92 1

Me Ph CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 87 93 1

CH₂Ph Me (CH₂)₂Ph 66 94 1

CH₂Ph Et Et 74 95 1

]—(CH₂)₅—[ CH₂Ph Me (CH₂)₂Ph 65 96 1

Et Et CH₂Ph

80 97 1

Et Et CH₂Ph Me (CH₂)₂Ph 85 98 1

Et Et CH₂Ph Et Et 77 99 1

Et Et CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 62 100 1

Et Et CH₂Ph

86 101 1

Me Ph CH₂Ph

68 102 1

Me Ph CH₂Ph Me (CH₂)₂Ph 77 103 1

Me Ph CH₂Ph Et Et 79 104 1

Me Ph CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 89 105 1

Me Ph CH₂Ph

71 106 1

CH₂Ph

61 107 1

]—(CH₂)₅—[ CH₂Ph

84 108 1

]—(CH₂)₅—[ CH₂Ph Me (CH₂)₂Ph 88 109 1

]—(CH₂)₅—[ CH₂Ph Et Et 98 110 1

]—(CH₂)₅—[ CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 97 111 1

]—(CH₂)₅—[ CH₂Ph

92 112 1

Et Et CH₂Ph

89 113 1

Et Et CH₂Ph Me (CH₂)₂Ph 97 114 1

Et Et CH₂Ph Et Et 94 115 1

Et Et CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 93 116 1

Et Et CH₂Ph

94 117 1

Me Ph CH₂Ph

99 118 1

CH₂Ph ]—(CH₂)₂—S—(CH₂)₂—[ 84 119 1

CH₂Ph

99 120 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph ]—(CH₂)₄—[ 75 121 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 67 122 0

CH₂Ph ]—(CH₂)₄—[ 72 123 0

CH₂Ph ]—(CH₂)₄—[ 66 124 0

CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 60 125 0

CH₂Ph ]—(CH₂)₄—[ 83 126 0

CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 76 127 0

CH₂Ph

73 128 0

CH₂Ph

71 129 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph ]—(CH₂)₄—[ 75 130 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 77 131 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph

64 132 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph

64 133 0

CH₂Ph ]—(CH₂)₄—[ 64 134 0

CH₂Ph ]—(CH₂)₄—[ 72 135 0

CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 70 136 0

CH₂Ph

62 137 0

CH₂Ph ]—(CH₂)₄—[ 85 138 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph ]—(CH₂)₄—[ 91 139 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 72 140 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph

67 141 0

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph

65 142 0

CH₂Ph ]—(CH₂)₄—[ 85 143 0

CH₂Ph ]—(CH₂)₄—[ 77 144 0

CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 64 145 0

CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 69 146 0

CH₂Ph ]—(CH₂)₄—[ 92 147 0

CH₂Ph

91 148 0

CH₂Ph

84 149 1

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph ]—(CH₂)₄—[ 87 150 1

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 75 151 1

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph

89 152 1

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph

65 153 1

CH₂Ph

71 154 1

CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 86 155 1

CH₂Ph

82 156 1

CH₂Ph

74 157 1

CH₂Ph

84 158 1

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 83 159 1

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph

94 160 1

]—(CH₂)₂—O—(CH₂)₂—[ CH₂Ph

79 161 1

CH₂Ph ]—(CH₂)₂—O—(CH₂)₂—[ 87 162 1

CH₂Ph

96 163 1

CH₂Ph ]—(CH₂)₄—[ 83 164 1

CH₂Ph

93 165 1

CH₂Ph

93 166 1

CH₂Ph

78

The separation of diastereomers and/or enantiomers is carried out by methods known to the person skilled in the art, for example by recrystallisation, chromatography or in particular HPLC chromatography, or crystallisation with an optionally chiral acid or base and separation of the salts, or chiral HPLC chromatography (Fogassy et al., Optical resolution methods, Org. Biomol. Chem 2006, 4, 3011-3030).

The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the described embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed broadly to include all variations within the scope of the appended claims and equivalents thereof. 

1. A substituted oxazole compound corresponding to Formula I:

wherein n is 0, 1 or 2; R¹ denotes optionally mono- or polysubstituted aryl or heteroaryl bonded via a C₁₋₃-alkylene chain; R² denotes optionally mono- or polysubstituted aryl or heteroaryl, or optionally mono- or polysubstituted aryl bonded via a C₁₋₃-alkylene chain; R³ and R⁴ independently denote optionally mono- or polysubstituted, saturated or unsaturated, branched or unbranched C₁₋₆-alkyl; optionally mono- or polysubstituted aryl; or optionally mono- or polysubstituted aryl bonded via a C₁₋₃-alkylene chain; or R³ and R⁴ together form a saturated or unsaturated 5-, 6- or 7-membered non-aromatic ring optionally containing a further heteroatom selected from the group consisting of S, O or N, said non-aromatic ring being optionally mono- or polysubstituted and optionally condensed to an aromatic ring; R⁵ and R⁶ independently denote H, or saturated or unsaturated, branched or unbranched C₁₋₆-alkyl, with the proviso that R⁵ and R⁶ are not simultaneously H; or R⁵ and R⁶ together denote —CH₂CH₂OCH₂CH₂—, or —(CH₂)₃₋₆—; R⁷ and R⁸ independently denote optionally mono- or polysubstituted, saturated or unsaturated, branched or unbranched C₁₋₆-alkyl; optionally mono- or polysubstituted aryl or heteroaryl bonded via a C₁₋₃-alkylene chain; or R⁷ and R⁸ together form a saturated or unsaturated 5-, 6- or 7-membered non-aromatic ring optionally containing a further heteroatom selected from the group consisting of S, O and N, said non-aromatic ring being optionally mono- or polysubstituted and optionally condensed to an aromatic ring; or a salt thereof with a physiologically acceptable acid.
 2. A compound as claimed in claim 1, wherein said compound is in the form of an isolated stereoisomer.
 3. A compound as claimed in claim 1, wherein said compound is in the form of a mixture of stereoisomers.
 4. A compound as claimed in claim 3, wherein said compound is in the form of a racemic mixture.
 5. A compound as claimed in claim 1, wherein R¹ denotes a phenyl group bonded via a C₁₋₃-alkylene chain, wherein said phenyl group is optionally mono- or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, or C₁₋₆-alkyl.
 6. A compound as claimed in claim 5, wherein R¹ denotes a benzyl group.
 7. A compound as claimed in claim 1, wherein R² denotes phenyl or thienyl optionally mono- or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, or C₁₋₆-alkyl; or a phenyl group bonded via a C₁₋₃-alkylene chain, wherein said phenyl group is optionally mono- or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, or C₁₋₆-alkyl.
 8. A compound as claimed in claim 7, wherein R² denotes phenyl optionally monosubstituted with Cl or F, or denotes thienyl.
 9. A compound as claimed in claim 1, wherein: R³ and R⁴ independently denote C₁₋₆-alkyl optionally mono- or polysubstituted with F, Cl, —CN, SH, S—C₁₋₆-alkyl, benzyl, OH, O-benzyl, O—C₁₋₆-alkyl, CO₂H, or CO₂—C₁₋₆-alkyl; or phenyl optionally mono- or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, or C₁₋₆-alkyl; or R³ and R⁴ together denote —CH₂CH₂OCH₂CH₂—, —CH₂CH₂NR⁹CH₂CH₂—, —(CH₂)₄₋₅—, or

wherein R⁹ denotes a C₁₋₆-alkyl group or a phenyl group bonded via a C₁₋₃-alkylene chain, wherein said phenyl group is optionally mono- or polysubstituted with F, Cl, Br, I, CN, NH₂, NH—C₁₋₆-alkyl, NH—C₁₋₆-alkyl-OH, N(C₁₋₆-alkyl)₂, N(C₁₋₆-alkyl-OH)₂, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, O—C₁₋₆alkyl-OH, C(═O)C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, or C₁₋₆-alkyl.
 10. A compound as claimed in claim 1, wherein R³ and R⁴ independently denote phenyl, ethyl or methyl; or R³ and R⁴ together denote —CH₂CH₂OCH₂CH₂—, —CH₂CH₂NR⁹CH₂CH₂—, —(CH₂)₄₋₅— or

wherein R⁹ denotes benzyl, 4-F-phenyl or 4-methoxyphenyl.
 11. A compound as claimed in claim 1, wherein R⁵ and R⁶ each denote CH₃.
 12. A compound as claimed in claim 1, wherein R⁷ and R⁸ independently denote benzyl or phenethyl optionally mono- or polysubstituted with F, Cl, CN, NO₂, SH, S—C₁₋₆-alkyl, OH, O—C₁₋₆-alkyl, CO₂H, CO₂—C₁₋₆-alkyl, CF₃, or C₁₋₆-alkyl; or R⁷ and R⁸ together denote —CH₂CH₂SCH₂CH₂—, —CH₂CH₂OCH₂CH₂—, —(CH₂)₅— or —CH₂CH₂NR¹⁰CH₂CH₂—, wherein individual H atoms can be replaced by branched or unbranched C₁₋₄-alkyl optionally mono- or polysubstituted with OH, OCH₃, CN, F, Cl, SH, SCH₃, CF₃ or benzyl; wherein R¹⁰ denotes phenyl, benzyl or phenethyl optionally mono- or polysubstituted with CH₃, OCH₃, OH, F, Cl, CN, SH, SCH₃ or CF₃.
 13. A compound as claimed in claim 12, wherein R⁷ and R⁸ independently denote methyl, ethyl, benzyl or phenethyl; or R⁷ and R⁸ denote —CH₂CH₂SCH₂CH₂—, —CH₂CH₂OCH₂CH₂—, —(CH₂)₄— or —(CH₂)₅—, —CH₂CH₂NR¹⁰CH₂CH₂—, wherein individual H atoms can be replaced by methyl or benzyl, and R¹⁰ denotes phenyl, 4-methoxyphenyl or benzyl.
 14. A compound as claimed in claim 1, selected from the group consisting of:
 17. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-piperidin-1-yl-methyl]-cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine;
 18. ((4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-methylphenylamine;
 19. ([4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-methylphenylamine;
 20. ([4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-methyl)-diethylamine;
 21. benzyl-[4-benzyl-2-({4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-diethylaminomethyl)-oxazol-5-yl]-methylamine;
 22. benzyl-{4-benzyl-2-[{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-(methylphenylamine)-methyl]-oxazol-5-yl}-methylamine;
 23. [(4-{[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 24. [(4-{[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 25. benzyl-(4-benzyl-2-{[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-piperidin-1-yl-methyl}-oxazol-5-yl)-methylamine;
 26. [(4-{[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 27. {[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine;
 28. {[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine;
 29. {[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine;
 30. benzyl-(4-benzyl-2-{diethylamino-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-oxazol-5-yl)-methylamine;
 31. {[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine;
 32. ({4-[[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-(4-benzylpiperazin-1-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 33. [(4-{[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-(4-fluorophenyl)-methyl]-dimethylamine;
 34. [4-benzyl-2-(diethylamino-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-oxazol-5-yl]-methylphenethylamine;
 35. [4-benzyl-2-(diethylamino-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-oxazol-5-yl]-diethylamine;
 36. ([4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-diethylamine;
 37. ([4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-methyl)-methylphenylamine;
 38. {4-benzyl-2-[{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-(methylphenylamine)-methyl]-oxazol-5-yl}-methylphenethylamine;
 39. [4-benzyl-2-({4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-piperidin-1-yl-methyl)-oxazol-5-yl]-diethylamine;
 40. [(4-{[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine;
 41. ([4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-methyl)-diethylamine;
 42. ([4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-methyl)-methylphenylamine;
 43. {4-benzyl-2-[{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-(methylphenylamine)-methyl]-oxazol-5-yl}-methylphenethylamine;
 44. [4-benzyl-2-((4-benzylpiperazin-1-yl)-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-methyl)-oxazol-5-yl]-diethylamine;
 45. [(4-{[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-piperidin-1-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 46. (4-benzyl-2-{[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-piperidin-1-yl-methyl}-oxazol-5-yl)-methylphenethylamine;
 47. (4-benzyl-2-{[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-piperidin-1-yl-methyl}-oxazol-5-yl)-diethylamine;
 48. ({4-[(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-piperidin-1-yl-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 49. (4-benzyl-2-{diethylamino-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-oxazol-5-yl)-methylphenethylamine;
 50. (4-benzyl-2-{diethylamino-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-methyl}-oxazol-5-yl)-diethylamine;
 51. {[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-diethylamine;
 52. {(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-methylphenylamine;
 53. ({4-[[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-(4-benzylpiperazin-1-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 54. (4-benzyl-2-{(4-benzylpiperazin-1-yl)-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-methyl}-oxazol-5-yl)-methylphenethylamine;
 55. ({4-[(4-benzylpiperazin-1-yl)-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 56. [(4-{2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine;
 57. [(4-{2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine;
 58. benzyl-[4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylamine;
 59. (1-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine;
 60. (1-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine;
 61. benzyl-[4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-diethylaminoethyl)-oxazol-5-yl]-methylamine;
 62. [{4-[2-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine;
 63. [{4-[2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine;
 64. [{4-[2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl-piperazin-1-yl)-ethyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine;
 65. [(4-{2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-(4-fluorophenyl)-methyl]-dimethylamine;
 66. benzyl-[4-benzyl-2-(2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylamine;
 67. (1-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine;
 68. (1-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine;
 69. (1-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine;
 70. benzyl-[4-benzyl-2-(1-diethylamino-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-methylamine;
 71. [{4-[2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine;
 72. [(4-{2-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 73. [(4-{2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 74. [(4-{2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 75. benzyl-(4-benzyl-2-{2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-1-piperidin-1-yl-ethyl}-oxazol-5-yl)-methylamine;
 76. [(4-{2-[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 77. {1-[4-benzyl-5-(4-benzylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine;
 78. {1-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine;
 79. {1-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine;
 80. benzyl-(4-benzyl-2-{1-diethylamino-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-oxazol-5-yl)-methylamine;
 81. ({4-[2-[4-benzyl-5-(4-benzyl-piperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 82. ({4-[2-[4-benzyl-5-(4-benzylpiperazin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 83. ({4-[2-[4-benzyl-5-(4-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 84. benzyl-(4-benzyl-2-{1-(4-benzylpiperazin-1-yl)-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-oxazol-5-yl)-methylamine;
 85. ({4-[2-[4-benzyl-5-(4-phenylpiperazin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 86. [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylphenethylamine;
 87. [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-diethylamine;
 88. (1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine;
 89. [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-diethylaminoethyl)-oxazol-5-yl]-methylphenethylamine;
 90. [4-benzyl-2-(2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-1-diethylaminoethyl)-oxazol-5-yl]-diethylamine;
 91. (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-diethylamine;
 92. (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-methylphenylamine;
 93. [4-benzyl-2-(1-(4-benzylpiperazin-1-yl)-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-methylphenethylamine;
 94. [4-benzyl-2-(1-(4-benzylpiperazin-1-yl)-2-{4-[(4-chlorophenyl)-dimethylaminomethyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-diethylamine;
 95. [4-benzyl-2-(2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1-piperidin-1-yl-ethyl)-oxazol-5-yl]-methylphenethylamine;
 96. (1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine;
 97. [4-benzyl-2-(1-diethylamino-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-methylphenethylamine;
 98. [4-benzyl-2-(1-diethylamino-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-oxazol-5-yl]-diethylamine;
 99. (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine;
 100. (1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-diethylamine;
 101. (1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-methylphenylamine;
 102. {4-benzyl-2-[2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1-(methylphenylamine)-ethyl]-oxazol-5-yl}-methylphenethylamine;
 103. {4-benzyl-2-[2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-1-(methylphenylamine)-ethyl]-oxazol-5-yl}-diethylamine;
 104. (1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-methylphenylamine;
 105. (1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-{4-[dimethylamino-(4-fluorophenyl)-methyl]-cyclohexyl}-ethyl)-methylphenylamine;
 106. [{4-[2-[4-benzyl-5-(3-methyl piperidin-1-yl)-oxazol-2-yl]-2-(4-benzyl piperazin-1-yl)-ethyl]-cyclohexyl}-(4-fluorophenyl)-methyl]-dimethylamine;
 107. [(4-{2-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 108. (4-benzyl-2-{2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-1-piperidin-1-yl-ethyl}-oxazol-5-yl)-methylphenethylamine;
 109. (4-benzyl-2-{2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-1-piperidin-1-yl-ethyl}-oxazol-5-yl)-dimethylamine;
 110. ({4-[2-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-piperidin-1-yl-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 111. [(4-{2-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-piperidin-1-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 112. {1-[4-benzyl-5-(3,5-dimethylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylamino-thiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine;
 113. (4-benzyl-2-{1-diethylamino-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-oxazol-5-yl)-methylphenethylamine;
 114. (4-benzyl-2-{1-diethylamino-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-oxazol-5-yl)-diethylamine;
 115. {1-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine;
 116. {1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-diethylamine;
 117. {1-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-[4-(dimethylaminothiophen-2-yl-methyl)-cyclohexyl]-ethyl}-methylphenylamine;
 118. ({4-[2-(4-benzylpiperazin-1-yl)-2-(4-benzyl-5-thiomorpholin-4-yl-oxazol-2-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 119. ({4-[2-[4-benzyl-5-(3-methylpiperidin-1-yl)-oxazol-2-yl]-2-(4-benzylpiperazin-1-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 120. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine;
 121. [{4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine;
 122. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-fluorophenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine;
 123. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine;
 124. [(4-{(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine;
 125. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine;
 126. [{4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine;
 127. [{4-[{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine;
 128. [{4-[[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine;
 129. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine;
 130. [{4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine;
 131. [[4-({4-benzyl-5-[4-(4-methoxy-phenyl)-piperazin-1-yl]-oxazol-2-yl}-morpholin-4-yl-methyl)-cyclohexyl]-(4-chlorophenyl)-methyl]-dimethylamine;
 132. [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-morpholin-4-yl-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine;
 133. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-fluorophenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine;
 134. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine;
 135. [(4-{(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine;
 136. [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-(4-chlorophenyl)-methyl]-dimethylamine;
 137. [{4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-(4-chlorophenyl)-methyl]-dimethylamine;
 138. ({4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 139. ({4-[(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-morpholin-4-yl-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 140. {[4-({4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-morpholin-4-yl-methyl)-cyclohexyl]-thiophen-2-yl-methyl}-dimethylamine;
 141. [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-morpholin-4-yl-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 142. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-fluorophenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine
 143. [(4-{(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 144. [(4-{(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-[4-(4-methoxyphenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 145. [(4-{[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-[4-(4-methoxy-phenyl)-piperazin-1-yl]-methyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 146. ({4-[(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 147. ({4-[{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 148. ({4-[[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-(3,4-dihydro-1H-isoquinolin-2-yl)-methyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 149. [{4-[2-(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-2-morpholin-4-yl-ethyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine;
 150. [{4-[2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-morpholin-4-yl-ethyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine;
 151. [[4-(2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-morpholin-4-yl-ethyl)-cyclohexyl]-(3-fluorophenyl)-methyl]-dimethylamine;
 152. [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-morpholin-4-yl-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine;
 153. [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine;
 154. [(4-{2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-[4-(4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine;
 155. [(4-{2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-[4-(4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine;
 156. [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-[4-(4-methoxy-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-(3-fluorophenyl)-methyl]-dimethylamine;
 157. [{4-[2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-(3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-cyclohexyl}-(3-fluorophenyl)-methyl]-dimethylamine;
 158. ({4-[2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-morpholin-4-yl-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine;
 159. {[4-(2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-morpholin-4-yl-ethyl)-cyclohexyl]-thiophen-2-yl-methyl}-dimethylamine;
 160. [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-morpholin-4-yl-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 161. [(4-{2-(4-benzyl-5-morpholin-4-yl-oxazol-2-yl)-2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 162. [(4-{2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-[4-(4-fluorophenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 163. [(4-{2-(4-benzyl-5-pyrrolidin-1-yl-oxazol-2-yl)-2-[4-(4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 164. [(4-{2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-[4-(4-methoxyphenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine;
 165. [(4-{2-[4-benzyl-5-(2,6-dimethylmorpholin-4-yl)-oxazol-2-yl]-2-[4-(4-methoxy-phenyl)-piperazin-1-yl]-ethyl}-cyclohexyl)-thiophen-2-yl-methyl]-dimethylamine; and
 166. ({4-[2-{4-benzyl-5-[4-(4-methoxyphenyl)-piperazin-1-yl]-oxazol-2-yl}-2-(3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-cyclohexyl}-thiophen-2-yl-methyl)-dimethylamine; or a salt thereof with a physiologically compatible acid.
 15. A pharmaceutical composition comprising a compound as claimed in claim 1 and at least one pharmaceutically acceptable carrier or auxiliary substance.
 16. A process for preparing a substituted oxazole compound as claimed in claim 1, said process comprising heating an aldehyde of Formula A with an amine of Formula B and an isonitrile amide of Formula C

wherein n and R1 through R8 have the meanings given in claim 1, in an organic solvent for 1-10 hours at a temperature between 30° and 100° C.
 17. A process as claimed in claim 16, wherein the solvent is methanol or ethanol, and the heating is effected at a temperature of 40° to 80° C.
 18. A method of treating a condition selected from the group consisting of pain, depression, urinary incontinence, diarrhea, pruritus, alcohol and drug misuse, drug dependency, lethargy and anxiety in a subject in need thereof, said method comprising administering to said subject a pharmacologically effective amount of a compound as claimed in claim
 1. 19. A method as claimed in claim 18, wherein said condition is pain.
 20. A method as claimed in claim 19, wherein said pain comprises acute pain, neuropathic pain or chronic pain. 